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ABSTRACT 
Vitamin D is traditionally known for its role in calcium homeostasis and bone metabolism. 
However, it has been demonstrated that numerous types of cells express the vitamin D 
receptor and it is now clear that the physiological roles of vitamin D extend beyond the 
maintenance of skeletal health. Vitamin D insufficiency, which is typically assessed by 
measuring the major circulating form of vitamin D, 25 hydroxyvitamin D (25(OH)D), has 
been associated with a number of disorders in people including hypertension, diabetes, 
cardiovascular diseases, cancer, autoimmune conditions and infectious diseases. Meta-
analyses have demonstrated that serum 25(OH)D concentrations are an important predictor 
of survival in people with a wide variety of illnesses and have been linked to all-cause 
mortality in the general human population.  
 
The role of vitamin D in non-skeletal disorders in cats and dogs is poorly understood. This is 
surprising since cats and dogs could act as excellent models for probing the biology of 
vitamin D. Vitamin D status in people is largely dependent on cutaneous production of 
vitamin D. This is influenced by many factors such as season, latitude and exposure to 
ultraviolet (UV) radiation. The interpretation of human studies investigating the effects 
vitamin D status on disease outcomes are therefore influenced by a number of confounding 
variables. Unlike humans, domesticated cats and dogs do not produce vitamin D cutaneously 
and obtain vitamin D only from their diet. The physiological functions and regulation of 
vitamin D are otherwise similar to humans. Most pets are fed commercial diets containing a 
relatively standard amount of vitamin D. Consequently, companion animals are attractive 
model systems in which to examine the relationship vitamin D status and health outcomes. 
Furthermore, spontaneously occurring model systems which did not require disease to be 
induced in healthy animals would allow the numbers of animals used in scientist research to 
be reduced. 
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This thesis aimed to define vitamin D homeostasis in companion animals in three disease 
settings; in cats with feline immunodeficiency virus (FIV) infection, dogs with chronic 
enteropathies (CE) and in hospitalised ill cats. Additional aims were to assess the prognostic 
significance of serum 25(OH)D concentrations in companion animals and the relationship 
between serum 25(OH)D concentrations and markers of inflammation. The hypothesis of 
this thesis was that vitamin status D would negatively correlate with presence of disease, 
markers of inflammation and disease outcomes. As similar findings have been demonstrated 
in human medicine, the hypothesis was that cats and dogs would be suitable models to 
investigate the role of vitamin D in human disease. 
 
This thesis demonstrates that in dogs with a CE serum 25(OH)D concentrations are 
negatively correlated with inflammation and are predictive of clinical outcomes. Vitamin D 
status was also lower in cats with FIV and importantly vitamin D status was predictive of 
short term mortality in hospitalised ill cats. This research will be of interest to veterinary 
surgeons and opens the possibility for clinical trials which examine if low vitamin D status is 
causally associated with ill health and whether vitamin D supplementation results in superior 
treatment outcomes in companion animals. This thesis also demonstrates the potential of cats 
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LAY SUMMARY 
Traditionally we have understood the importance of vitamin D in maintaining bone health 
and preventing diseases such as rickets.  However, in recent years there has been a greater 
understanding about the other roles played by vitamin D in maintaining good health. These 
include regulating immune function and inflammation, heart function, the activity of a 
number of hormones and maintaining normal blood pressure. 
 
In human medicine, vitamin D deficiency is a common finding in patients with a number of 
different diseases and has been shown to be predictive of clinical outcomes such as 
treatment success and the risk of mortality. Accordingly, there is a growing interest in the 
role of vitamin D in the treatment and prevention of many illness. Less is known about the 
potential role of vitamin D in diseases of cats and dogs. This information is of great interest 
to veterinary surgeons and pet owners, particularly in predicting health outcomes. In 
addition, assessing vitamin D in people is difficult as a number of variables affect vitamin D 
concentrations in humans. The most important of these is exposure to sunlight and dietary 
intake. In contrast to people, cats and dogs do not produce vitamin D as a result of sunlight 
exposure and tend to consume commercial pet food supplemented with standard amounts of 
vitamin D. Therefore, exploring the effects of blood vitamin D concentrations on health 
outcomes in cats and dogs may provide a model to better understand the effect of vitamin D 
on human illness. 
 
The aim of this research was to explore the association between vitamin D and infectious 
diseases by studying cats with feline immunodeficiency virus, to examine the relationship 
between vitamin D and all-cause mortality in a population of sick cats and to investigate the 
relationship between vitamin D status on the risk of mortality and markers of inflammation 
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in dogs with a chronic enteropathy. The results showed that cats infected with feline 
immunodeficiency virus had lower vitamin D status than healthy cats. The research also 
found that vitamin D status was predictive of mortality in hospitalised ill cats and of poor 
clinical outcome in dogs with a chronic enteropathy. Again, like in human medicine, an 
association between low 25(OH)D status and markers of inflammation was observed in dogs 
with a chronic enteropathy. These results highlight the potential for investigating the effects 
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CHAPTER ONE  
Thesis Overview 
1.1 Introduction   
Traditionally vitamin D biology has been understood in terms of its importance in 
maintaining skeletal health and serum ionised calcium concentrations via the actions of 
vitamin D receptors in the intestines, bones and kidney. In recent decades it has been 
appreciated that the vitamin D receptor is found in most tissues [1].  Additionally, many 
tissues also contain the enzyme CYP27B1[1]. This enzyme converts vitamin D to its active 
form calcitriol. As a result there is an increasing body of research dedicated to exploring the 
non-classical actions of vitamin D, including the potential associations between serum 
vitamin D concentrations and a number of medical conditions as well as possible clinical 
applications for vitamin D analogues. Low serum vitamin D concentrations, which are 
typically assessed by measuring the vitamin D metabolite 25-hydroxyvitamin D (25(OH)D), 
have been associated with a number of illnesses and health outcomes in human medicine [2]. 
Less research has been performed in companion animal species. Low serum 25(OH)D 
concentrations have been documented in dogs diagnosed with: congestive heart failure [3], 
spirocercosis [4], protein losing enteropathy [5, 6], renal disease [7] and neoplasia [8, 9]. 
Low vitamin D status has been reported in cats with inflammatory bowel disease or small 
cell intestinal lymphoma [10] and in feline mycobacterial infections [11].  Despite evidence 
that serum 25(OH)D concentrations are reduced in a number of canine and feline diseases, 
the clinical significance of low 25(OH)D concentrations in companion animal practice and 
how disease influences serum vitamin D concentrations is poorly understood. Currently 
knowledge regarding the significance of low serum 25(OH)D concentrations in companion 
animal medicine is limited to studies which have demonstrated that lower serum vitamin D 
concentrations are associated with poorer treatment responses in dogs treated for atopic 
dermatitis [12] and poor outcomes in dogs with congestive heart failure [3]. Before 
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considering the possible benefits of vitamin D supplementation to cats and dogs with 
hypovitaminosis D, there is a need for further assessment of the potential importance of 
vitamin D in maintaining the health of cats and dogs.  
 
1.2 Overview of Vitamin D Biology  
Vitamin D activation 
The active form of vitamin D is a steroid hormone [13]. In people, the pro-hormone vitamin 
D3 (Cholecalciferol) is synthesised cutaneously when the cholesterol metabolite 7-
dehydrocholesterol is exposed to ultraviolet (UV) light [14]. Alternatively, exogenous 
vitamin D3 can be obtained in the diet from sources such as oily fish and vitamin D2 can be 
obtained in the diet from some vegetable sources [15]. Unlike people, cats and dogs are 
unable to produce vitamin D cutaneously and are therefore dependent on obtaining dietary 
vitamin D3 from meat sources [16]. The inability of cats to synthesise vitamin D is the result 
of low cutaneous concentrations of the vitamin D precursor 7-dehydrocholesterol, which in 
turn is due to an increase in activity of the enzyme 7-dehydrocholesterol reductase [17]. 
Similar mechanisms might account for the lack of cutaneous vitamin D synthesis in dogs. 
 
Both vitamin D2 and vitamin D3 are inactive pre-hormones. Activation requires further 
metabolism to form the biologically active form of vitamin D, calcitriol (1,25(OH)2D) 
[18].Vitamin D metabolites are transported to target tissues for further metabolism bound to 
vitamin D binding protein (DBP) [19, 20]. Approximately 80 to 90% of circulating 
25(OH)D and calcitriol is transported bound to DBP, with 10-20% being bound to albumin. 
Just 0.02–0.05% of 25(OH)D circulates unbound [21]. The first step in activating vitamin D 
occurs in the liver, where vitamin D3 or D2 under goes hydroxylation to form 25-
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hydroxyvitamin D (25OH D) [19]. This step is largely controlled by the mitochondrial 
enzyme CYP27A1 [1]. The action of this enzyme is unregulated and is substrate dependent 
[1]. Therefore, 25(OH)D is a reliable indicator of combined dietary intake and cutaneous 
synthesis of vitamin D [20]. 25-hydroxyviatmin D is then transported to the kidneys where it 
is subsequently converted to calcitriol [22].  DBP- bound 25(OH)D, binds to megalin 
receptors on the proximal renal tubule cell plasma membrane and is transported into the cell 
for hydroxylation to occur [23]. This hydroxylation step is catalysed by the mitochondrial 
enzyme 25-hydroxyvitamin D-1α-hydroxylase (CYP27B1) [19]. Although the kidney is the 
major site of calcitriol synthesis, CYP27B1 is found in a number of extra-renal tissues where 
it acts to synthesise calcitriol for local consumption as an intracrine or paracrine factor [1]. 
 
The activity and transcription of renal CYP27B1 is stimulated by parathyroid hormone 
(PTH) and inhibited by fibroblast growth factor-23 (FGF-23) and calcitriol[19, 24, 25]. The 
renal synthesis of calcitriol can also be stimulated by calcitonin for non-calcaemic needs 
when normocalacaemic [26]. Control of calcitriol production in extra-renal tissues is not 
affected by these hormones [1]. The release of PTH is regulated by serum ionised calcium 
and serum phosphorus concentrations and calcitriol [27]. PTH is primarily released in 
response to hypocalcaemia but may also be induced by hyperphosphatemia [28]. Calcitriol 
acts on the intestines and kidneys to promote the uptake of dietary calcium and phosphate 
and reabsorption of calcium from the glomerular infiltrate in the kidneys. Rising calcitriol 
concentrations reduce further calcitriol production by inhibiting CYP21B1 activity and 
activating the enzyme responsible for calcitriol catabolism; 24(OH)ase (CYP24) [19].  
CYP24 can also hydroxylate 25(OH)D, reducing the pool of 25(OH)D available for 
activation to calcitriol [19]. CYP24 metabolises calcitriol to form inactive metabolites 
including 24,25-dihydroxyvitamin D (24,25(OH)2D) and 1,24,25(OH)3D which leads to the 
production of calcitroic acid [19]. CYP24 is an extremely active enzyme, however, it is 
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inactivated in vitamin D deficiency as transcription of the gene coding for CYP24 is 
activated by calcitriol [18]. This ensures that calcitriol metabolism only occurs when 
sufficient calcitriol is available. Calcitriol also negatively controls its own synthesis by 
negatively regulating PTH secretion. Calcitriol may inhibit the synthesis of PTH via 
conversion of 25(OH)D to calcitriol within the parathyroid gland itself and by directly 
activating VDR receptors on the parathyroid gland [29, 30].  Fibroblast growth factor-23, is 
a phosphaturic hormone which can also inhibits calcitriol synthesis. As calcitriol increases 
phosphate absorption, FGF-23 therefore, acts to reduce phosphate concentrations via 
suppression of CYP21B1 and activation of CYP24 [19].  
 
Assessment of vitamin D status 
It is possible to measure a number of vitamin D metabolites. However, vitamin D status is 
typically only assessed by measuring 25(OH)D concentrations [31]. Although calcitriol is 
the active form of vitamin D, assessing calcitriol concentrations does not provide accurate 
information regarding vitamin D sufficiency or deficiency. This is because, in the face of 
vitamin D deficiency, falling calcium concentrations will result in PTH activation. This will 
increase calcitriol concentrations in an attempt to maintain normocalcaemia. Therefore, even 
in the face of vitamin D deficiency, calcitriol concentrations in humans may be normal or 
elevated [31].  Furthermore, assessment of serum calcitriol levels is difficult because the 
half-life of calcitriol is 4-6 hours, and circulating calcitriol concentrations are a thousand 
fold less than 25(OH)D [31]. Unlike calcitriol production, the hepatic production of 
25(OH)D is not actively regulated, meaning that serum 25(OH)D directly reflects either 
dietary vitamin D intake or cutaneous synthesis [31].  The half-life of 25(OH)D is life of 
approximately 2–3 weeks reflecting vitamin D intake and synthesis over this period of time 
[31].  
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Therefore, 25(OH)D concentrations provide the most accurate assessment of vitamin D 
status [31].   
 
The vitamin D receptor 
Like other steroid hormones, the action of calcitriol is mediated via nuclear hormone 
receptors. The vitamin D receptor (VDR) is a member of the superfamily of nuclear 
hormone receptors which also includes receptors for thyroid hormones and retinoic acid [1]. 
The VDR is found across a number of cell types, were it typically forms a heterodimer with 
the retinoid X-receptor in order to interact with vitamin D responsive elements (VDRE) [1, 
32]. Vitamin D responsive elements are DNA sequences found in the promoter region of 
genes regulated by vitamin D [1]. When calcitriol binds to the VDR conformational changes 
occur allowing binding of VDR-complexes to VRDE resulting in expression or repression of 
specific genes [1]. Transcription requires other molecules to act as co-activators or co-
repressors. Co-repressors block VDR mediated gene transcription in the absence of calcitriol 
and are displaced when calcitriol binding recruits co-activators to the VDR [1]. The VDR 
can also exert non-genomic actions at caveolae in cell membranes [32]. Binding of calcitriol 
to membrane associated VDRs activates second messenger systems, such as G protein-
coupled receptors, phosphatidylinositol-3′-kinase (PI3K), phospholipase C, or protein kinase 
C (PKC). This can lead to a number of outcomes such as opening of voltage gated channels 
for electrolytes, thus allowing vitamin D to also exert rapid effects on cells [32]. 
 
Calcaemic and skeletal actions of vitamin D  
Calcitriol acts alongside parathyroid hormone to maintain adequate serum ionised calcium 
and phosphorus concentrations for bone mineralisation. Maintaining serum ionised calcium 
concentrations also allows normal neuromuscular function [23]. When sufficient dietary 
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calcium is available vitamin D increases the uptake of dietary calcium to maintain 
normocalcaemia. This is achieved by the action of calcitriol on intestinal epithelial cells 
where it promotes the expression of calcium channels, calcium ATPase pumps and calcium-
binding protein [33, 34]. The absorption of phosphate is also increased as calcitriol induces 
expression of the sodium-phosphate co-transporter required for intestinal phosphate 
absorption [35]. Calcitriol also facilitates reabsorption of calcium and phosphorus from the 
glomerular filtrate in the renal distal tubule [36]. When insufficient dietary calcium is 
available or when insufficient vitamin D is available to promote the absorption of dietary 
calcium, mobilization of calcium and phosphorus from bone can occur [18]. Vitamin D 
deficiency results in bone disorders such as rickets, osteomalacia and osteoporosis [25, 37].  
Calcitriol and PTH are reported to promote the differentiation of osteoclasts to increase bone 
resorption [38, 39]. This is achieved by inducing osteoblasts to express receptor activator 
nuclear factor-κB ligand (RANKL). Osteoclast precursors express RANK receptors which 
bind to RANKL on osteoblasts [23, 40]. Binding of RANK receptors to RANKL causes the 
differentiation and activation of osteoclasts, promoting bone resorption by releasing 
hydrochloric acid and collagenases thus increasing serum calcium concentrations [23, 40]. 
Therefore, in times of profound calcium deficiency vitamin D could act alongside PTH to 
promote bone resorption to maintain serum calcium concentrations. However, supra-
physiological doses of calcitriol are required for osteoclast differentiation to occur and 
evidence from in-vivo experiments suggests that typically vitamin D actually inhibits bone 
resorption [38, 39]. In-vivo, bone resorption is largely regulated by PTH.  In general the 
effects of vitamin D are to reduce bone resorption as calcitriol inhibits the release of PTH 
and therefore antagonises PTH-induced bone resorption [38]. Calcitriol also regulates bone 
development and bone health by stimulating osteoblasts to produce ALP, collagen, 
oestocalcin and oestopontin [41]. 
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Non-skeletal actions of vitamin D  
The VDR receptor is found on numerous cell types unrelated to calcium and phosphate 
homeostasis [36].  Many cells contain express CYP21B, which when activated results in 
local calcitriol production [1]. The local activation of vitamin D likely allows intracrine and 
paracrine messaging for the local regulation of cell functions and tissue growth [1]. 
Important actions of vitamin D beyond its effects on calcium balance includes regulation of 
the immune system, regulation of cell proliferation and differentiation, regulation of 
secretion of insulin and cardiovascular functions as discussed below.  
 
Vitamin D and immune functions 
Within the immune system vitamin D regulates cell proliferation, cellular differentiation and 
immunological functions to maintain immune tolerance and to promote protective immunity 
[42]. Within the acquired immune system, vitamin D can directly and indirectly act on 
lymphocytes to influence immune cells responses. Both T and B lymphocytes express VDR, 
and vitamin D acts to inhibit lymphocyte proliferation [43, 44]. T-helper lymphocytes 
(CD4+ T cells) modulate the function of other immune cells by releasing cytokines in 
response to specific antigens. The development of CD4+ T cells into: Th1 cells (which 
promote cellular immunity), Th 2 cells (which promote humoral immunity by stimulating B 
cells to secrete immunoglobulin), Th17 cells (which help protect against fungal pathogens 
and specific extracellular bacteria), or immunotolerant T-regulatory cells (which function to 
modulate the immune system in order maintain tolerance to harmless self-antigens and 
regulate the inflammatory actions of effector T-cells) determines the phenotype of an 
immune response. Vitamin D can alter T-helper lymphocyte phenotypes, causing a shift 
away from Th1 (cellular immunity) to a Th2 phenotype (humoral immunity), inhibiting 
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inflammatory Th17 responses and promoting the induction of T-regulatory cells [42, 45, 46]. 
Calcitriol also down regulates harmful, pro-inflammatory immune responses by auto-
reactive Th-17 lymphocytes [47]. Cytotoxic T cells, which are directly involved in cell 
mediated immunity, also express the VDR, but calcitriol has less of an anti-proliferative 
effect on CD8+ cells [48]. However, calcitriol activity regulates cytotoxic T-cell cytokine 
production [49] and regulates the proliferation of cytotoxic T-cells in response to certain 
stimuli [50]. Vitamin D also regulates antibody producing B-cells by limiting on going 
proliferation, differentiation and secretion of immunoglobulin by activated B-cells and 
inducing B-cell apoptosis [44, 51]. 
 
Dendritic cells are antigen-presenting cells. The main function of dendritic cells is to process 
antigenic material and present it to T-lymphocytes. Cytokines produced by antigen 
presenting cells directs the phenotype of T-cells responses. Antigen presenting cells are key 
targets for the immunomodulatory effects of calcitriol [52]. Studies have consistently 
demonstrated that vitamin D inhibits the maturation of dendritic cells [45, 53, 54]. Vitamin 
D promotes the induction of tolerogenic dendritic cells which promote regulatory T-cell 
responses. This is achieved by down-regulating the expression of the co-stimulatory 
molecules CD40, CD80 and CD86, which are required for T cell activation, by reducing the 
expression of inflammatory cytokines such as interleukin-12 (IL-12) and by increasing 
production of the anti-inflammatory cytokine IL-10 [52]. Vitamin D-treated dendritic cells  
can also induce auto-reactive  T-cell apoptosis [55]. Vitamin D has additionally been shown 
to increase the expression of immunoglobulin-like transcript 3 (ILT3) [52]. This protein 
belongs to a family of inhibitory receptors expressed by human monocytes and dendritic 
cells which have been shown to negatively regulate the activity of antigen presenting cells 
[56]. As calcitriol promotes up-regulation of inhibitor ILTs this may be an additional 
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mechanism by which vitamin D can promote immune tolerance [52, 56]. Therefore, the 
combined actions of vitamin D on the acquired immune system are to promote generation of 
tolerogenic rather than immunogenic dendritic cells, to promote a regulatory T cell 
phenotype and to suppress the inflammatory effects of effector T cell functions. 
 
Vitamin D also exerts effects on the innate immune system. Vitamin D is known to enhance 
the innate immune response to bacteria. Antigen binding to toll-like receptors on innate 
immune cells increases expression of the VDR and CYP27B1 [57]. The local availability of 
activated vitamin D-VDR complexes is therefore increased during innate immune responses. 
This allows vitamin D-VDR complexes to bind to VDRE in target genes within these cells 
[42]. Genes regulated by VDRE include those associated with the production of anti-microbial 
peptides such as cathelicidin [57-59]. Vitamin D can therefore enhance the anti-bacterial 
functions of innate immune cells in response to antigenic stimulation. Vitamin D also has a 
negative feedback role on innate immune cells activity. For example, in macrophages the local 
production of calcitriol leads to down-regulation of toll-like receptor signalling, preventing 
excessive immune responses [60]. Local vitamin D production has also been demonstrated to 
reduce pro-inflammatory cytokine production in monocytes and macrophages [61]. In 
addition to its functions on leukocytes, vitamin D may also modulate innate immunity by its 
effects on barrier function at mucosal and epithelial surfaces. Epithelial cells also contain 
CYP27B1 [62, 63]. Vitamin D receptors may therefore function to maintain protective barrier 
functions at these sites. For example, in the gastrointestinal tract calcitriol can alter the 
expression of tight junction proteins [64]. In the skin, vitamin D is also important in the 
production of lipids that play a role in barrier function [62]. 
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Given the known functions of vitamin D in the immune system, numerous studies have 
investigated the association between vitamin D status and both autoimmune diseases and 
infectious diseases. Observational studies have demonstrated that patients with vitamin D 
deficiency could be at greater risk for developing immune-mediated diseases [65]. 
Associations between low vitamin D status and autoimmune diseases are reported for 
condition such as systemic lupus erythematous and multiple sclerosis [66, 67], rheumatoid 
arthritis and psoriasis [68]. Vitamin D deficiency is also associated with increased 
autoimmune responses in healthy people [69]. However, despite these associations the 
design of these studies cannot conclude that the association between vitamin D status and 
risk of immune mediated disease is definitely a causal relationship.  
 
The best studied link between bacterial infections and low vitamin D status is in tuberculosis 
(TB) infections in people [70, 71]. Not only are serum 25(OH)D concentrations low in 
people with TB, but supplementation with vitamin D appears to be beneficial in treating 
pulmonary TB infections [71, 72]. Low serum 25(OH)D concentrations are also a risk factor 
for infections such as pneumonia and acute lower respiratory infections [73, 74], sepsis [74] 
and Clostridium difficile infections [75]. In addition low 25(OH)D status has been associated 
with viral infections such as influenza [76] and Human Immunodeficiency Virus (HIV) [77, 
78]. Vitamin D deficiency is associated with poor disease outcomes in viral infections such 
as chronic hepatitis B [79] and hepatitis C infections [80]. Additionally, sub-optimal vitamin 
D status and subnormal calcitriol concentrations have been associated with lower CD4 + 
lymphocyte counts in HIV infected people and HIV progression and acquired immune 
deficiency syndrome (AIDs) related morbidity and survival [81-84]. Therefore, a 
predisposition to infectious diseases or poorer immune responses to infections may occur in 
individuals with a low vitamin D status, although this has not been definitely demonstrated.  
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Vitamin D and endocrine functions 
Vitamin D has been shown to be important in the regulation of hormone secretion and 
endocrine functions. The regulation of PTH secretion is important for both bone and calcium 
homeostasis. However, vitamin D also influences the secretion of other hormones. It has 
been demonstrated that vitamin D can stimulate beta pancreatic cells to secrete insulin [85-
87] and vitamin D receptor knock-out mice have reduced insulin secretory capacity [88].  
Vitamin D deficiency has also been related to impaired insulin action in type 2 diabetes 
mellitus, metabolic syndrome and obesity [89-91]. Furthermore poor vitamin D status is 
epidemiologically associated with diabetes mellitus [92, 93]. The renin-angiotensin system 
(RAAS) is also regulated by vitamin D. This has been demonstrated in VDR knock out 
mice, where excessive renin production is associated with hypertension and cardiac 
hypertrophy [94-96]. Inappropriate activation of the RAAS can result in hypertension. 
Observational studies have reported an association between vitamin D-deficiency and high 
blood pressure [97, 98]. The effects of vitamin D on regulation of the renin-angiotensin 
system may explain the epidemiological association between subnormal vitamin D 
concentrations and hypertension in people. This hypothesis is supported by evidence of 
higher circulating angiotensin concentrations in vitamin D insufficient people [99]. There 
appears to be a small benefit in supplementing hypertensive patients with vitamin D [100].  
 
Vitamin D and cardiovascular disease 
In addition to regulating the renin-angiotensin system, which is important for cardiac health, 
there is also evidence that vitamin D has physiological effects on cardiomyocytes, vascular 
smooth muscle and the vascular endothelium [101]. Murine experiments have demonstrated 
that vitamin D has important effects in modulating and maintaining cardiac cell structure and 
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function [102]. Secondary hyperparathyroidism is associated with vitamin D deficiency. 
Excessive PTH concentrations are related to increased blood pressure and increased cardiac 
contractility, leading to cardiomyocyte hypertrophy and fibrosis [103]. Meta-analyses of 
several observational studies suggests that there is an inverse association between serum 
25(OH)D concentrations and the risk of cardiovascular disease and death due to 
cardiovascular disease [104, 105]. Vitamin D concentrations are also predictive for the 
incidence of cardiovascular disease and death over a 13 year period [106]. Poor 25(OH)D 
status is also commonly seen in patients with congestive heart failure [107]. In veterinary 
medicine, an association between congestive heart failure and low serum 25(OH)D 
concentrations has been reported in dogs [3]. This study also demonstrated that like in 
human medicine, patients with low serum 25(OH)D concentrations had poorer outcomes.  In 
addition to its reported effects on cardiac function and the RAAS, vitamin D may also be 
protective in cardiovascular disease due to its previously discussed effects in modulating 
inflammation and the immune system [62].  
 
Vitamin D and cancer 
In vitro and in vivo studies indicate that calcitriol promotes cell differentiation, regulates cell 
proliferation, promotes cellular apoptosis and has antiangiogenic properties [33]. These 
functions therefore provide a mechanistic explanation as to how vitamin D could prevent the 
development of cancer. Vitamin D can block a number of pathways associated with cellular 
proliferation such as the β-catenin, MAP kinase 5 (MAPK5), nuclear factor κB (NF-kB) and 
transforming growth factor β (TGFβ) [33, 108]. Calcitriol can also activate cyclin-dependent 
kinase inhibitors such as p21 and p27; inhibit growth factors including insulin like growth 
factor 1 (IGF-I) and epidermal growth factor receptor [108, 109] and can promote 
expression of growth regulatory genes such as TGF-β [110]. Furthermore calcitriol induces 
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apoptosis by down-regulating anti-apoptotic genes and up-regulating pro-apoptotic genes 
[111, 112]. The anti-inflammatory effects of calcitriol decrease prostaglandin synthesis 
which is required for tumour angiogenesis and metastasis implicating sub-normal vitamin D 
concentrations in the development of neoplasia [113, 114]. Due to its effects on apoptosis 
and cellular proliferation, the potential for vitamin D to influence the development, outcome 
and treatment of neoplastic diseases has received a great deal of attention. Numerous studies 
have documented an association between low vitamin D status and many types of cancer 
[115-118]. Vitamin D supplementation may have some benefits in cancer prevention [119], 
although this has not been universally reported from clinical trials [120, 121]. Low serum 
25(OH)D concentrations have also been reported in cats with intestinal small cell lymphoma 
[10], dogs with mast cell tumours [9] and dogs with splenic neoplasms [8]. 
 
Vitamin D and muscle function 
Vitamin D may be important for muscle function. It has been suggested that binding of 
calcitriol to the nuclear VDR in skeletal muscle results in the synthesis of muscle proteins 
[122]. This hypothesis is supported by studies which show an increase in type II muscle 
fibres after treatment with vitamin D [123]. Vitamin D may also have non-genomic effects 
on muscle tissues via effects on calcium signalling and the sarcoplasmic reticulum [124]. 
Observational investigations have demonstrated a positive association between higher 
25(OH)D status and muscle strength [125]. A meta-analysis of 8 randomized interventional 
studies shows that vitamin D supplementation lowered the incidence of falls in older people 
by 72% compared to those receiving a placebo [126], suggesting vitamin D can increase 
muscle strength in this population. 
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Vitamin D and renal disease 
Low 25(OH)D concentrations are common in patients with chronic kidney disease and 
plasma 25(OH)D concentrations are an independent predictor of disease progression and 
death in patients with chronic kidney disease [127, 128]. Supplementation with exogenous 
vitamin D appears to offer survival benefits [129, 130]. The relationship between calcitriol 
and the renin-angiotensin system may help explain the association between low serum 
25(OH)D concentrations and poor outcomes in renal disease. Causes of low serum 25(OH)D 
concentrations in patients with chronic kidney disease may include decreases in megalin, 
which is the binding protein for vitamin D found in the proximal tubule of the kidney. A 
decrease in megalin associated with reduced renal mass may reduce renal reabsorption of 
vitamin D [131]. In addition, vitamin D and vitamin D binding protein are lost in protein 
losing nephropathies [132]. Furthermore, impaired renal function and reduced renal mass 
limit the amount CYP2B1 available for production of the active vitamin D metabolites 
[133]. Phosphate retention associated with declining renal function will also increase FGF-
23 concentrations and down regulate the conversion of 25(OH)D to calcitriol [133, 134]. 




Low Serum Vitamin D concentrations; cause or consequence of disease? 
 
It is clear that vitamin D exerts pleiotropic effects on a number of cells types and therefore, 
low vitamin D concentrations could conceivably contribute to ill health in a number of 
diseases. Not only have low serum 25(OH)D concentrations been associated with a number 
of diseases but poor vitamin D status has also been linked to all-cause mortality in the 
general human population [44] and in a population of sick foals [135]. Meta-analyses have 
demonstrated that serum 25(OH)D concentrations are an important predictor of survival in 
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people with a wide variety of illnesses [45-48]. However, it is unclear if low serum vitamin 
D concentrations are cause or consequence of ill health. Despite the association between low 
vitamin D status and numerous non-skeletal diseases, meta-analyses of randomised 
controlled trials investigating the effects of vitamin D supplementation often do not support 
the hypothesis that vitamin D concentrations are causally associated with disease risk or 
health outcomes [105, 136]. Factors associated with poor health such as poor diets and a lack 
of dietary vitamin D [137-139], lack of exposure to sunlight [140-142] and obesity [143, 
144] are all associated with poor vitamin D status. Therefore, low vitamin D status may be a 
marker for other causes of ill health. Furthermore, lower vitamin D concentrations are 
common with increasing age [145, 146] and the prevalence of many diseases would be 
expected to be higher in elderly individuals.   
 
Recent research suggests that sunlight exposure may have other health benefits beyond 
stimulating the production of 25(OH)D in human skin. Lui et al have demonstrated that 
exposure to UV light reduces blood pressure and the authors propose that this is linked to the 
cutaneous production of nitric oxide [147]. Therefore, serum 25(OH)D concentrations may 
be a biomarker for other benefits of sunlight exposure and the apparent associations between 
serum 25(OH)D concentrations and a number of diseases may not be directly related to 
vitamin D status. Clearly, as cats and dogs do not cutaneously produce vitamin D, the 
association between serum 25(OH)D concentrations and diseases in companion animals is 
unlikely to be related to sunlight exposure. 
 
As low vitamin D status is commonly reported in a number of inflammatory diseases, it is 
hypothesised that low serum vitamin D concentrations are a consequence of inflammation 
rather than a cause of inflammatory illnesses. Serum 25(OH)D concentrations have been 
shown to decrease following elective surgical procedures, coupled with increases in 
inflammatory markers such as C-reactive protein (CRP), suggesting that vitamin D is a 
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negative acute phase reactant [148]. Increases in pro-inflammatory cytokines have been 
proposed as the cause of decreases in serum 25(OH)D seen in acute inflammation. For 
example, declining serum 25(OH)D concentrations over several weeks following elective 
knee arthroplasty corresponded with increases in serum pro-inflammatory cytokines [149]. 
 
Assessing the role of vitamin D on human health outcomes is hampered by a large number 
of environmental variables which influence serum vitamin 25(OH)D concentrations. These 
include factors such as ethnicity [139, 150, 151], dietary intake of vitamin D [137-139], 
seasonality [152],  latitude and exposure to sunlight [140-142], obesity [143, 144], age [145] 
and gender [153]. Exploring the relationship between serum 25(OH)D concentrations and 
health outcomes in a model system in which many of these confounding factors are avoided 
would be of significant interest. Furthermore, a model system which did not require disease 
to be induced in otherwise healthy animals would allow the number of animals used in 
scientific research to be reduced. Most cats and dogs eat a commercial diet which is 
supplemented with a similar amount of vitamin D [154].  In addition, cats and dogs do not 
synthesize vitamin D cutaneously meaning that serum 25(OH)D concentrations are not 
influenced by exposure to UV radiation and that vitamin D is not biomarker for other 
beneficial effects of sunlight exposure [16, 17]. Therefore, as fewer confounding variables 
affect vitamin D assessment in cats and dogs, companion animal could provide a novel 
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1.3 Thesis Objectives 
The importance of vitamin D in maintaining human health is unclear. Even less is known 
about the clinical importance of low serum 25(OH)D concentrations in ill cats and dogs, 
despite low 25(OH)D having been reported in a number of companion animals diseases. The 
general objective of this thesis was to define vitamin D homeostasis in companion animals 
by investigating serum 25(OH)D concentrations in hospitalised ill cats, dogs with chronic 
enteropathies (CE) and cats with feline immunodeficiency virus (FIV) infection.  The aim 
was to assess the prognostic significance of serum 25(OH)D concentrations in companion 
animals and to assess the possible relationship between serum vitamin D concentrations and  
inflammation. Furthermore, if the findings of this thesis mirrored those seen in human 
practice, then this thesis aimed to assess if cats and dogs could provide a model system in 
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CHAPTER 2          
 
Investigation of vitamin D status as a predictor of 30 day mortality in hospitalised cats 
 
2.1 Introduction 
Vitamin D insufficiency has been associated with a number of disordersin people including 
hypertension [155], diabetes mellitus [156], cardiovascular diseases [104], cancer [116], 
autoimmune conditions [157] and infectious diseases [83, 158, 159]. Furthermore, low 
serum 25(OH)D concentrations have also been linked to all-cause mortality in the general 
human population [160]. Meta-analyses have demonstrated that serum 25(OH)D 
concentrations are an important predictor of survival in people with a wide variety of 
illnesses [105, 161-163]. One of the most striking findings is the negative association 
between serum 25(OH)D concentrations and all-cause mortality. This finding was consistent 
across study populations, sexes, age groups and seasons [161, 162].  
 
Despite the associations between mortality and lower serum 25(OH)D concentrations, many 
randomised intervention trials with vitamin D supplements have found little effect on 
mortality, suggesting that low serum vitamin D concentrations may be a consequence of 
serious illness rather than being causally associated with mortality [164, 165]. However, one 
meta-analysis has demonstrated that intakes of normal amounts of vitamin D are associated 
with reduced mortality [166] and another recent meta-analysis also showed that vitamin D 
supplementation reduced mortality in elderly people [167]. Higher 25(OH)D concentrations 
may also be associated with an increased risk of mortality. In a population of patients 
hospitalised in intensive care, supra-physiological serum concentrations of 25(OH)D were 
associated with an increased risk of death [168].  Other studies have demonstrated similar 
findings. For example, in an observational study investigating the effect of pre-
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hospitalisation serum 25(OH)D concentrations in patients admitted to two American 
hospitals, the risk of all-cause mortality 90 days after admission to hospital was greater for 
patients with serum 25(OH)D concentration less than 20 ng/mL and greater than 60ng/mL 
[169]. Similar findings have been reported in the general population in the United States 
[170], in primary care patients in Copenhagen [171], in elderly women [172] and in elderly 
men [173]. The association between all-cause mortality and elevated vitamin D 
concentrations has not been consistently reported. This may be due differences in study 
design between epidemiological studies investigating the prognostic significance of serum 
25(OH)D concentrations. Many of the studies examined the effects of vitamin D as a non-
continuous variable based on quintiles, quartiles or tertiles [105, 161, 174, 175]. By 
grouping very high serum 25(OH)D concentrations with more moderate concentrations the 
association with higher vitamin D status may have been lost in these studies. Furthermore, in 
many studies, relatively few patients had very high serum vitamin D concentrations, 
meaning many studies may have been underpowered to examine the effect of higher serum 
vitamin D concentrations.  
 
A large number of factors are known to influence serum 25(OH)D concentrations in people. 
These factors include: ethnicity [139, 150, 151], diet [137-139], seasonality [152], latitude 
and exposure to sunlight [140-142], obesity [143, 144], age [145] and gender [153].  This 
makes interpreting the results of observational studies documenting an association between 
serum 25(OH)D and mortality in humans particularly challenging. Investigating the 
relationship between serum 25(OH)D concentrations and all-cause mortality in a model 
mammalian system in which many of these confounding factors are avoided would be of 
significant interest. Advantages of investigating the role of 25(OH)D on health outcomes in 
cats include a more standard dietary intake of vitamin D since almost all cats which attended 
the referral veterinary hospital in this study eat a commercial diet which is supplemented 
with a similar amount of vitamin D [154]. In addition, cats do not synthesise vitamin D 
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cutaneously meaning that serum 25(OH)D concentrations are not influenced by exposure to 
UV radiation [16, 17]. 
 
Investigating the role of serum 25(OH)D concentrations and all-cause mortality in cats 
would be of interest to veterinary surgeons since it is presently difficult to accurately predict 
mortality in hospitalised ill cats. The identification of clinical measures which were 
predictive of mortality would be extremely helpful in providing much needed prognostic 
information to owners of ill cats. 
 
Hypothesis 
The hypothesis of this study was that cats with lower serum 25(OH)D concentrations would 
have higher mortality at 30 days post admission to hospital than cats which were vitamin D 
replete. This would make client owned, domesticated cats which acquired spontaneous 
diseases a suitable model in which to study the relationship between serum 25(OH)D 
concentrations and all-cause mortality in people. 
 
Objectives 
The objectives of this study were to; 
 
 Measure serum 25(OH)D concentrations in a general hospital population of ill cats 
and to assess if serum 25(OH)D concentrations were a predictor of short term (30 
day) all-cause mortality. 
 
 Measure other clinical variables including; age, sex, breed, appetite scores, serum 
albumin, creatinine, potassium, sodium, total calcium concentrations, total packed 
cell volume and total white cell counts to investigate their ability to predict short 
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term outcomes in ill cats. The potential of these factors to cofound any relationship 
between mortality and serum 25(OH)D concentrations in cats was also investigated. 
 
 
2.2 Material and Methods 
 
Study Population 
Consecutive cats examined at the Royal (Dick) School of Veterinary Studies, Hospital for 
Small Animals were considered eligible for inclusion in the study. Informed consent for the 
use of residual clinical blood samples for research purposes was obtained at admission for 
each cat enrolled. Ethical approval for the study was obtained from the University of 
Edinburgh’s Veterinary Ethical Review Committee. 
 
Clinical records were reviewed for each cat enrolled. The age, sex and breed were recorded 
for each cat. Survival data was obtained from clinical records or follow up telephone calls to 
clients and referring veterinary surgeons for each cat at day 30 after first presentation to the 
Hospital for Small Animals. The appetite of the cats was graded as normal or reduced.  The 
following clinical information was extracted from the clinical records of each cat enrolled: 
white blood cell count, packed cell volume (PCV), serum albumin concentrations, serum 
creatinine concentration, serum sodium concentrations, serum potassium concentrations and 
total serum calcium concentration. Haematology variables were measured on an ADVIA(r) 
2120i System with Autoslide (Siemens Medical Solutions Diagnostics Ltd California, USA). 
Biochemistry parameters (serum sodium, potassium, creatinine, albumin and total calcium) 
concentrations were measured on an ILab650 biochemistry analyser, (Diamond Diagnostics, 
USA). 
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Following handling of blood samples for routine diagnostic procedures, serum samples were 
stored initially at -20°C and later moved to -70oC for longer term storage until 25(OH)D 
concentrations were measured as a batch. Previous studies have indicated that 25(OH)D is 
stable when stored at -20oC [176]. Serum concentrations of 25(OH)D2 and 25(OH)D3 were 
determined by liquid chromatography tandem mass spectrophotometry (LC-MS/MS) using 
an ABSciex 5500 tandem mass spectrophotometer (Warrington, UK) and the Chromsystems 
(Munich, Germany) 25OHD kit for LC-MS/MS following the manufacturers’ instructions 
(intra- and inter-assay CV 3.7% and 4.8% respectively). This Supraregional Assay Service 
laboratory is accredited by CPA UK (CPA number 0865) and has been certified as proficient 
by the international vitamin D Quality Assurance Scheme (DEQAS). Total 25(OH)D is 
defined as the sum of 25(OH)D2 and 25(OH)D3. The laboratory measuring the vitamin D 
metabolites was blinded to the clinical data from the enrolled cats. In addition, veterinary 
surgeons caring for the enrolled cats were not aware of 25(OH)D results during the clinical 




Initially, 25(OH)D concentrations were compared between cats which died within 30 days of 
sampling to cats which survived 30 days by a Mann-Whitney U test. In order to investigate 
for the presence of confounding variables a standard binary logistic regression model of 
death by 30 days was constructed. A range of clinical and biochemical data including sex, 
age, breed, total white blood cells, packed cell volume and serum concentrations of albumin, 
total calcium, creatinine, sodium and potassium were included, as was an assessment of 
appetite as a binary variable (normal or reduced). Initially 25(OH)D concentrations were 
included as a linear predictor within the logistical regression model. Serum 25(OH)D 
concentrations were also divided into 3 categories based on 33% and 66% tertiles treating 
the variable as a three level factor and also as low versus middle and high categories 
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combined.  Akaike’s information criteria (AIC – a parameter penalised measure of model 
fit) was used to stepwise select variables which were to be retained to identify a final model 
with minimum AIC (i.e. best parameter penalised fit).  P values for individual variables were 




A total of 99 cats were recruited to the study. The median age of the cats was 96 months. 
There were 3 intact males, 56 neutered males, 1 intact female and 39 neutered female cats. 
Breeds enrolled in the study included; 62 Domestic Short Hairs, 8 Domestic Long Hairs,  6 
Maine Coons, 5 Burmese, 3 Bengals, 2 Tonkinese, 2 Siamese, 2 Ragdolls, 2 Burmese 
crosses, 2 Oriental Short Hairs, 1 Manx Cat, 1 British Short Hair, 1 Chinchilla, 1 Burmilla 
and 1 Abyssinian.  
 
 There was a significant difference between the 25(OH) D concentrations of cats which were 
alive (n=80) compared to cats which had died at 30 days (n=19) (p=0.0022, fig.1). 














Figure 1: Box and whiskers plot of serum concentrations of 25(OH)D in cats which died or were alive at 30 days post admission. Box extends 
from 25th-75th percentiles with solid line representing the median value. Whiskers extend to 5th-95th percentiles
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Using serum 25(OH) D concentrations as a linear predictor of survival within the logistic 
regression model, none of the variables, including 25(OH)D concentration, were significant 
predictors of mortality. Since several studies in human medicine have also shown a non-
linear relationship between vitamin D status and mortality [160, 171, 177], serum 25(OH)D 
concentrations were also represented as a categorical variable. When serum 25(OH)D 
concentrations were considered as a categorical variable, cats with a 25(OH)D concentration 
in the lower tertile had an increased risk of mortality compared to cats in the middle tertile 
reference category (Table 1). There was no significant difference in survival between cats in 
the upper and middle tertile (Table 1). The only other parameters which were associated 
with an increased risk of mortality at 30 days post hospital admission were serum potassium 
concentrations and a reduced appetite (Table 1).  
 
Variable Odds ratio (95% CI) P value 
Potassium  4.23 (1.36-14.59) 0.0153 
Reduced appetite 4.05 (1.17-17.04) 0.0370 
25(OH)D category low 
(<73.6nmol/l) 




Reference category Reference category 
25(OH)D category high 
(>110.05nmol/l) 
1.31 (0.21-8.66) 0.7681 
 
Table 1: Results of logistic regression model including vitamin D as three tertile 
categorical variable. Table only shows significant variables. (AIC = 85.50) 
 
Based on the results of the three tertile model and the epidemiological data which links low 
vitamin D status to poor health outcomes [161], the middle and upper tertiles were combined 
into a single binary predictor in a third model. A serum 25(OH)D concentration in the lower 
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tertile remained predictive of 30 day mortality (Table 2). Again, serum potassium 
concentrations and a reduced appetite were the only other parameters included in the third 
model which were predictive of survival (Table 2). 
 
 
Variable Odds ratio (95% CI) P value 
Potassium 4.14 (1.34-14.21) 0.0161 
Reduced appetite 4.02 (1.16-16.83) 0.0379 
25(OH)D category low 
(<73.6nmol/l) 
8.27 (2.54-31.52) 0.0008 
 
Table 2: Results of logistic regression model combining vitamin D as a categorical 
variable using vitamin D as a binary predictor of lower tertile versus middle and upper 
tertiles combined. Table only shows significant predictors. (AIC = 83.58) 
 
2.4 Discussion 
The central finding of this study demonstrates that hospitalised ill cats with low serum 
25(OH)D concentrations were less likely to survive 30 days post hospitalisation. Using a 
regression model which included serum 25(OH)D concentrations as a linear variable, none 
of the 12 clinical, biochemical and haematological parameters, including 25(OH)D 
concentrations, were predictive of mortality. However, when a second analysis in which 
serum 25(OH)D concentrations were included as a categorical variable was performed, 
results demonstrated that low vitamin D status was an independent predictor of short term 
mortality. 
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The finding that there was a relationship between low serum 25(OH)D concentrations and 
mortality is consistent with numerous human studies [161, 163, 178]. In addition, the 
observation that there was not a linear relationship between vitamin D status and survival is 
also consistent with studies in human patients [160, 171]. Several human studies have 
reported that there is minimal benefit of having high serum 25(OH)D concentrations and a 
number have linked high vitamin D status to negative health outcomes [169, 171]. There 
wasn’t a significantly increased risk of death for cats with higher vitamin D concentrations 
in this study. However, the possibility that higher serum 25(OH)D concentrations could be 
associated with poor health outcomes, should be borne in mind when setting hypotheses in 
any future studies investigating the association of vitamin D and health outcomes in cats and 
in any prospective clinical trials employing vitamin D supplementation.  
 
It is unclear if serum 25(OH)D concentrations are directly associated with health outcomes 
or are just a reflection of disease severity. Alternatively interventions and treatments 
commonly given to ill patients may also affect serum 25(OH)D concentrations. One study 
suggests reduced vitamin D concentrations, particularly in the critically ill where patients are 
commonly given large volumes of intravenous fluids, may be a consequence of 
haemodilution [179]. Many of the cats enrolled in this study may have received fluid 
therapy, which could have affected the results of this study. However, blood samples from 
the cats enrolled in this study were collected at the time of admission to the referral hospital, 
prior to the administration of any medical interventions. Therefore, unless the cats had been 
given large volumes of fluids by the referring veterinary surgeons prior to referral, 
haemodilution is unlikely to be a significant contributor to low serum 25(OH)D 
concentrations in this study. Some medications including glucocorticoids [180] and anti-
epileptic drugs [181] can influence vitamin D metabolism in humans. However, it is unclear 
whether many commonly used drugs can influence vitamin D metabolism in companion 
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animals. However, it has been previously shown that glucocorticoids do not alter vitamin D 
metabolism in dogs [182]. As many cats would have received some form of medical 
treatment prior to referral, the inability to assess the impact of certain medications of vitamin 
D homeostasis is a limitation of this study. 
 
Reverse causation or confounding variables could account for the association between low 
25(OH)D concentrations and 30 day mortality. For example, vitamin D status could be a 
marker for other variables which cause poor health and increase the risk of mortality. For 
example, in people a link between obesity and low 25(OH)D has been reported [183, 184] 
and obesity is associated with increased all-cause mortality [185]. Further work is required 
to see if environmental or lifestyle factors could account for lower serum 25(OH)D 
concentrations in cats. Another potential explanation for the association between poor 
outcomes and vitamin D status is the hypothesis that vitamin D is a negative acute phase 
reactant. A negative acute phase reactant is a substance whose plasma concentrations 
decreases in response to inflammation. It has been shown that serum vitamin D binding 
protein concentrations and 25(OH)D concentrations are likely to decrease as part of the 
systemic inflammatory response [186]. This may explain why serum 25(OH)D 
concentrations tended to be lower in in the cats which died as inflammatory processes may 
have been more marked in these cats compared to inflammatory processes in surviving cats.  
 
Observational studies are unable to determine if low serum 25(OH)D are a cause of 
consequence of illness and are inherently affected by confounding variables and the 
possibility of reverse causality. To assess the importance of serum 25(OH)D concentrations 
as a predictor of mortality in human medicine, investigators have studied the effect of 
genetic mutations in the enzymes 7-dehydrocholesterol reductase (DHCR7) and vitamin D 
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25-hydroxylase (CYP2R1) on the risk of mortality [187]. Mutations in genes coding for 
these enzymes lead to low serum 25(OH)D concentrations [187]. Genetic variants that 
mirror the biological effects of a modifiable environmental exposure (such as low vitamin D 
status), can investigate the risk of variables on disease outcomes without being confounded 
by a range of other environmental, social or behavioural factors [188]. In addition, reverse 
causation is also avoided in these studies [188].  Research conducted by Afzal et al suggests 
that lower serum 25(OH)D concentrations due to genetic mutations were associated with 
both all-cause mortality and cancer mortality [187]. There was no association between these 
genetic mutations and other risk factors for mortality [187]. The authors of this study 
therefore concluded that these results suggest that low 25(OH)D may genuinely be causally 
associated with poor health outcomes.  
 
There are many potential explanations for why low vitamin D status could causally be 
associated with increased all-cause mortality. One possible important factor is the role of 
vitamin D metabolites on immune function and inflammation. The vitamin D receptor is 
expressed on many immune cell types and it is clear that vitamin D can modulate both the 
innate and acquired immune responses via effects on monocytes, macrophages, dendritic 
cells and lymphocytes [189, 190]. One of the best studied links between vitamin D 
metabolites and immune function in critically ill patients is the association between vitamin 
D status and anti-bacterial immune responses. This includes the effects of calcitriol on 
stimulating the production of the anti-bacterial peptide cathelicidin in neutrophils, 
macrophages, monocytes and epidermal cells [59]. One prospective cohort study of critically 
ill patients found that lower total 25(OH)D levels were associated with lower human 
cathelicidin (hCAP18) concentrations and that lower hCAP18 levels were associated with a 
greater risk of both sepsis and 90-day mortality [191]. Similar changes may also occur in 
cats and could partially account for the association between low 25(OH)D and mortality in 
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the cats in this study population, particularly as some of these cats presented with serious 
infections such as a pyothorax. 
 
The renin-angiotensin system is negatively regulated by vitamin D [96, 99]. Up-regulated 
renin-angiotensin activity is associated with systemic hypertension, renal dysfunction, 
vascular damage [192] and cardiac hypertrophy [193]. Feeding transgenic rats which 
overproduce angiotensin and renin a diet deficient in vitamin D aggravates hypertension and 
end target organ damage [194]. Furthermore, supplementing vitamin D deficient patients 
with hypertension blunts systemic renin-angiotensin activity [195]. The vitamin D receptor 
has also been shown to block the renin-angiotensin system in a rodent model of acute lung 
injury [196]. Increased renin has been associated with microvascular dysfunction and organ 
failure in patients with sepsis [197]. Therefore, interactions between calcitriol and the renin-
angiotensin system may provide another mechanistic link to explain the association between 
poor vitamin D status and an increased risk of mortality. 
 
The pleiotropic extra-skeletal effects of vitamin D extend to vascular function [198] and the 
response of vascular endothelium to injury [199]. Stress to the endothelium causes 
proliferation of vascular smooth muscle, which is inhibited by vitamin D metabolites [200]. 
Vascular dysfunction is also associated with an increase in thrombotic events. Vitamin D 
analogues have been shown in-vitro to down regulate the expression of pro-thrombotic 
proteins by human aortic smooth muscle cells [201]. As thrombosis is an important cause of 
mortality and morbidity in veterinary patients [202], this may also account for potential 
associations between serum 25(OH)D concentrations and mortality in this population of 
cats. Similarly cardiopulmonary dysfunction is commonly recognised as a cause of 
mortality. Serum 25(OH)D concentrations have been associated with lung function [203] 
and vitamin D is also important for cardiac function and health [204].  
Page | 40 
 
 
Hypocalcaemia has also been reported as a predictor of poor outcome in critically ill human 
patients [205, 206]. In feline practice, hypocalcaemia has been identified as a negative 
prognostic indicator in cats with pancreatitis [207]. Hypovitaminosis D may contribute to the 
hypocalcaemia seen in critically ill humans, although this is only typically seen with 
profound hypovitaminosis D [208]. However, it is possible that moderate hypovitaminosis D 
could contribute to hypocalcaemia alongside other risk factors associated with critical illness 
[209]. In this population of cats, total calcium concentrations were not associated with 
survival and therefore alterations in calcium status secondary to changes in serum 25(OH)D 
concentrations are unlikely to account for the association between lower 25(OH)D and 
mortality in this study. However, measurement of ionised calcium may have provided a 
more accurate assessment of calcium status.  
 
This study also demonstrated that reduced appetite was an independent predictor of short 
term mortality in cats. This finding is similar to human studies where reduced appetite has 
been linked to poor health outcomes in elderly patients [210]. However, serum 25(OH)D 
concentrations remained a significant predictor of mortality when the results were corrected 
for reduced appetite. This suggests that the association between low serum vitamin D 
concentrations and mortality is not simply due to reduced dietary intake of vitamin D in 
hospitalised cats.  
 
The study also demonstrated that potassium concentrations were linked to mortality with 
increasing potassium concentrations associated with poor survival outcomes. High serum 
potassium concentrations have been associated with mortality in critical care patients, even 
when increases in potassium are modest [211] and in patients with cardiac and renal disease 
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[212]. The mechanism(s) by which hyperkalaemia influences mortality are unclear. However 
raised potassium concentrations can result in altered neurological, cardiac and muscular 
functions [211]. Furthermore, declining renal function is also associated with hyperkalaemia 
[213] and hyperkalaemia has been shown to be associated with serious infections and 
haemorrhage [211] in people, which may in part explain its association with mortality.  
 
In contrast to human medicine, little is known about the factors which are involved in all-
cause mortality in cats. Previous studies have focused on cats admitted to an intensive care 
unit (ICU), rather than across a wider hospital population [214, 215]. Therefore, the use of 
serum 25(OH)D concentrations to predict survival in a general hospital population is an 
important feature of this study.  A previously reported predictor of feline survival is the 
Feline Acute Patient Physiologic and Laboratory Evaluation (Feline APPLE) Score [215]. 
This scoring system has been validated only for feline ICU patients and requires several 
clinical and diagnostic parameters to be assessed. A univariable measure such as serum 
25(OH)D concentration may provide a simpler and more readily usable predictor of 
mortality. This study therefore provides valuable information about a possible prognostic 
marker for use in feline practice. 
 
One significant limitation of this study in assessing mortality is that ill cats may be 
euthanized by their owner for a number of reasons, including financial limitations. However, 
the cats which were euthanized in this study were generally seriously unwell, requiring 
tertiary referral care. Euthanasia was generally performed only when clinicians advised 
owners that the prognosis is was very poor. Clinicians were blinded to vitamin D status at 
the time of hospitalisation; recommendations for euthanasia were therefore not based on 
serum 25(OH)D concentrations. Euthanasia is often the predominant cause of death in 
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veterinary patients for ethical reasons. Therefore, when assessing a potential biomarker for 
mortality it would be unreasonable to exclude cases which died as a result of euthanasia. 
 
It cannot be concluded that serum 25(OH)D is causally linked to mortality from the finding 
that low vitamin D status is an independent risk factor for 30 day mortality in hospitalised, 
ill cats. This would require further prospective studies, including randomised, placebo 
controlled supplementation studies of cats with low vitamin D status. In light of the finding 
that cats with 25(OH)D concentrations in the upper tertile had a similar incidence of 
mortality as cats in the middle tertile, future studies could focus on assessing whether 
correction of hypovitaminosis D improves health outcomes. This approach is supported by 
observations from human trials in critically ill patients [216]. Similarly, a study investigating 
the effects of vitamin D on cardiovascular morbidity and mortality, revealed that although 
supplementation improved overall survival, the effects were only significant in vitamin D 
deficient patients [217]. 
 
2.4 Conclusion 
In conclusion, this study supports the hypothesis that low serum vitamin D status is 
predictive of 30 day mortality in hospitalised cats. The finding that low serum 25(OH)D 
concentrations are negatively correlated with survival supports the initiation of follow up 
clinical trials to examine the influence of vitamin D supplementation on disease outcome. 
The study also indicates that domesticated cats with spontaneous illnesses may provide a 
valuable alternative to rodent models in which the effects of vitamin D on health outcomes 
can be probed without the need to induce disease in otherwise healthy animals.  
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CHAPTER 3 
Investigation of the relationship between vitamin D status and clinical outcomes in 
dogs with chronic enteropathies 
 
3.1 Introduction 
Chronic enteropathies in dogs are a major cause of morbidity and mortality. A diagnosis of a 
chronic enteropathy (CE) is made in dogs with a chronic history of gastrointestinal signs 
such as weight loss, vomiting and diarrhoea. Gastrointestinal biopsies from these dogs 
reveals the presence of an inflammatory infiltrate, for which no underlying aetiology is 
found following a full diagnostic evaluation [218]. The pathogenesis of canine CE is 
considered to be multifactorial and includes factors such as abnormal mucosal immunity, 
disrupted epithelial barrier function, altered intestinal microbial flora, environmental 
variables and genetic factors [218, 219].  Inflammatory bowel diseases in man, most notably 
Crohn’s disease and ulcerative colitis are thought to be caused by similar factors [220]. 
 
It has previously been shown that dogs with a CE have lower serum concentrations of 
25(OH)D than healthy dogs and hospitalised dogs with non-gastrointestinal illnesses [5, 6]. 
In addition, it has also been demonstrated that the severity of the clinical signs, as assessed 
by the canine inflammatory bowel activity index (CIBDAI), correlates with serum 25(OH)D 
concentrations in dogs with a CE [5]. However, the prognostic significance of serum 
25(OH)D concentrations has not been investigated in dogs with a CE. 
 
In contrast, the relationship between vitamin D status and IBD has been extensively 
explored in human medicine.  In human patients with IBD, vitamin D insufficiency or 
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deficiency is a frequent finding [221-224].  Higher predicted vitamin D status has been 
associated with a reduced risk of developing Crohn’s disease [225]. Amongst people with 
IBD, 25(OH)D concentrations are related to disease severity scores and patient quality of 
life scores [226-228]. Low plasma 25(OH)D concentrations have also been associated with 
an increased risk of surgery and hospitalisation in patients with either Crohn’s disease or 
ulcerative colitis [229]. Additionally, normalization of 25(OH)D concentrations in patients 
with Crohn’s disease has been associated with a reduction in the risks associated with 
Crohn’s related surgery [229]. Vitamin D status has also been linked to IBD treatment 
outcomes, as low pre-treatment vitamin D status has been associated with reduced durability 
of response to anti–tumour necrosis factor (TNF-α) therapy [230]. Studies have also 
demonstrated improvements in disease activity scores and quality of life scores in Crohn’s 
disease patients supplemented with oral vitamin D [231, 232].  
 
Hypothesis 
The hypothesis of this study was that the vitamin D status would not be different in dogs that 
died or were euthanised due to complications associated with their CE compared to dogs 
which were alive at follow up or had died due to diseases unrelated to a CE. 
 
Objectives 
The aims of this study were to; 
 Measure serum concentrations of 25(OH)D, alongside CIBDAI scores, serum 
albumin concentrations and total serum calcium concentrations in dogs with a 
confirmed diagnosis of CE and known clinical outcome. 
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 To assess the effect of serum 25(OH)D concentrations and age, CIBDAI scores, 
albumin and total calcium concentrations on outcome in dogs with a CE and to 
assess the possible prognostic significance of serum vitamin D concentration in 
dogs with a CE. 
 
 
3.2 Material and Methods 
The records of dogs referred to the Hospital for Small Animals, Royal Dick School of 
Veterinary Studies for investigation of chronic gastrointestinal disease (more than three 
weeks in duration) between 2007 and 2013 were retrospectively reviewed. Dogs were 
considered eligible for inclusion in the study if they had presenting clinical signs consistent 
with a CE which included any of the following: vomiting, diarrhoea, increased borborygmi, 
abdominal pain, increased or decreased appetite and weight loss. All dogs were considered 
eligible if they had histopathological evidence of inflammation within the small or large 
intestines and if there were no clinically relevant abnormalities detected on haematology, 
biochemistry or abdominal ultrasonography, which were not attributable to CE.  In addition, 
a stored frozen serum sample from each dog collected at the time of diagnosis was required 
for retrospective analysis of 25(OH)D concentrations. Haematology variables (Total white 
blood cell count, mature neutrophils, band neutrophils, lymphocytes, monocytes, 
eosinophils, basophils, total red blood cell counts, packed cell volume, haemoglobin, mean 
cell volume, mean cell haemoglobin concentration and platelet number) were measured on 
ADVIA(r) 2120i System with Autoslide (Siemens Medical Solutions Diagnostics Ltd 
California, USA).  Biochemistry variables (albumin, ALT, ALP, bile acids, bilirubin, total 
calcium, creatinine, globulin, phosphate, potassium, sodium, chloride, urea and glucose) 
were measured on an ILab650 biochemistry analyser, (Diamond Diagnostics, USA). Clinical 
records were also reviewed for the results of faecal parasitology. Canine inflammatory 
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bowel disease activity index scores were calculated as follows: appetite, activity levels, 
vomiting, faecal consistency, faecal frequency and weight loss were each scored from 0-3. A 
score of 0 indicated no changes were present, a score of one indicated mild changes, 2 
moderate changes and 3 severe changes. In addition a score of one point was added if the 
faeces contained blood or mucus. The maximum possible score was 20. The area of 
intestinal tract which was biopsied (duodenum or duodenum and colon) was determined 
based on presenting clinical signs and was at the discretion of the primary clinician 
managing the case. A diagnosis of CE was made if there was histological evidence of 
intestinal inflammation and no clear underlying cause. Dogs were classified as survivors if 
they were alive at the time of follow up or if they had died from diseases unrelated to their 
CE. Dogs were classified as non-survivors if they had died or were euthanised as a 
consequence of their CE.  
 
Vitamin D analysis 
Serum samples retained for 25(OH)D measurement were frozen after being used for routine 
biochemical analysis and were stored at –70°C before being sent to the laboratory for 
analysis on dry ice. Serum 25(OH)D has been shown to be stable under these conditions 
[233]. Serum concentrations of 25(OH)D were measured as previously described in detail 
[234, 235]. Samples were extracted using acetonitrile and applied to C18 Silica Sep-paks. 
Separation of metabolites was by straight phase high performance liquid chromatography 
(HPLC) (Waters Associates, Milford, MA, USA) using a Hewlett-Packard Zorbax-Sil 
Column (Hichrom, Reading, UK) eluted with hexane:propan-2-ol:methanol (92:4:4). Serum 
25(OH)D2 and 25(OH)D3 were measured separately by application to a second Zorbax-Sil 
Column eluted with hexane:propan-2-ol (98:2) and quantified by ultraviolet absorbance at 
265nm and corrected for recovery (sensitivity 5nmol/L, intra- and inter-assay coefficients of 
variation 3·0% and 4·2%, respectively) [236]. Total 25(OH)D was defined as the sum of 
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25(OH)D2 and 25(OH)D3. This laboratory is accredited by CPA UK (CPA number 0865) 
and has been certified as proficient by the international vitamin D Quality Assurance 
Scheme (DEQAS).  
 
Histopathology 
Where available, the slides of the original duodenal biopsies were reviewed by a single 
veterinary pathologist. Some samples could not be retrieved from archived stores. A 
qualitative scoring system (WSAVA Standards for the Diagnosis of Gastrointestinal 
Inflammation in Endoscopic Biopsy Samples) [237], was used to assess the degree of 
inflammation present. The template for this system assesses the following histological 
changes: (villous stunting, epithelial injury, crypt distension, lacteal dilatation, and mucosal 
fibrosis) and inflammatory infiltrates (intraepithelial lymphocytes, lamina propria 
lymphocytes and plasma cells, lamina propria eosinophils, and lamina propria neutrophils). 
The changes for each of the variables listed were graded as normal (0), mild (1), moderate 
(2) or severe (3). The sums of all these variables were added together to determine an 
intestine inflammatory score which ranged from 0 (normal) to 30 (very severe). 
 
Outcome 
For each dog enrolled, follow up data was obtained by reviewing clinical records and by 
telephone contact with referring veterinary surgeons and owners.  Dogs were recorded as 
survivors if they were alive at follow up or had died due to a non CE related illnesses or non-
survivors if dogs had died or were euthanized due to complications associated with CE.   
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Statistical analysis 
Univariable measures were compared between dogs which survived and non-surviving dogs 
using a Mann-Whitney U test. A Fisher’s exact test was used to compare the sex of 
surviving and non-surviving dogs. A binary logistic regression model was used to estimate 
the association between outcome (survivors versus non-survivors) and serum 25(OH)D 
concentrations conditional on a range of other candidate predictors. Stepwise selection of 
variables was used to minimise Akaike Information Criteria (AIC) which is a parameter 
penalized measure of model fit. Intestine inflammatory scores were classified into three 
approximate tertiles (low <7, medium 7-8, high>8) for the regression model. The statistical 
analysis was performed using R statistical system (R Development Core Team (2012).   
 
Ethical Review 
Informed consent for the use of residual clinical blood samples for research purposes was 
obtained at admission for each dog enrolled. Ethical approval for the study was obtained 




Forty-one dogs were included in the study. There were 15 non-survivors and 26 survivors. In 
the non-survivors group, 2 dogs were intact males, 7 were neutered males, 1 was an intact 
female and 5 were neutered females. In the survivors group, 7 dogs were intact males, 11 
were neutered males and 8 were neutered females. Breeds in the non-survivor groups 
included Border Collie (n=1), Boxer (n=3), Cavalier King Charles Spaniel (n=1), Cross 
Breed (n=3), German Short Haired Pointer (n=1), Hungarian Vizsla (n=1), Italian 
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Greyhound (n=1), Pyrenees Mountain Dog (n=1), Springer Spaniel (n=1), Staffordshire Bull 
Terrier (n=1) and West Highland White Terrier (n=1). In the survivors groups breeds 
included Border Terrier (n=1), Boxer (n=7), Cocker Spaniel (n=1), Cavalier King Charles 
Spaniel (n=1), Chinese Crested (n=1), Cross Breed (n=1), Irish Setter (n=2), Labrador 
Retriever (n=2), Lurcher (n=2), Rottweiler (n=1), Shar pei (n=1), Shetland Sheep Dog (n=1), 
Springer Spaniel (n=1), Staffordshire Bull Terrier (n=1), Toy Poodle (n=2) and Yorkshire 
Terrier (n=1).  
 
Clinical Findings 
The median duration of clinical signs at diagnosis was 3 months in the non-survivors (range 
1 month-10 months) and 3.5 months (range 0.75 months-24 months) in the survivors group. 
Haematology, biochemistry and abdominal ultrasonography findings did not reveal any 
clinically relevant abnormalities in any of the 41 dogs which could not be attributed to their 
CE. Faecal parasitology was performed in 36 dogs and did not reveal evidence of parasitic 
infection in any of the samples. Twelve dogs underwent gastroduodenoscopy and 29 dogs 
had both gastroduodenoscopy and colonoscopy. Histopathological examination of duodenal 
biopsies in the non-survivors revealed lymphoplasmacytic enteritis (5) and mixed 
lymphoplasmacytic and eosinophilic enteritis (10). In the survivor group histopathological 
diagnosis based on duodenal biopsies included lymphoplasmacytic enteritis (8) and mixed 
lymphoplasmacytic and eosinophilic enteritis (18). Follow up data for the survivor group 
ranged from 18-75 months (median 27 months).  In the non-survivors group the follow up 




Page | 50 
 
Outcome 
Fifteen dogs died or were euthanized as a result of their CE (table 1). The age of the dogs at 
presentation which subsequently died or were euthanised due to their chronic enteropathy 
ranged from 9 to 114 months (median 96 months). Dogs which subsequently died had been 
treated with dietary changes and antibiotics (n=2), dietary changes, prednisolone and 
antibiotics (n=7) and dietary changes, antibiotics, prednisolone and other 
immunosuppressive medications (n=6). Twenty six dogs did not die as a result of 
gastrointestinal disease (tables 1). Sixteen dog were alive at follow up and ten had died due 
to non-gastrointestinal diseases. The age of the dogs in the survivors group ranged from 6 to 
96 months (median 60.5 months). Dogs in this group were treated with dietary changes and 
antibiotics (n=10), dietary changes and prednisolone (n=1), dietary changes, prednisolone 
and antibiotics (n=3), dietary changes, prednisolone, antibiotics and other 
immunosuppressive drugs (n=1), diet alone (n=10) and gastroprotectants (n=1). 
 
Univariable analysis revealed that serum 25(OH)D, albumin and total calcium 
concentrations were significantly lower in non-survivors compared to survivors (table 1, fig. 
1). Age and CIBDAI scores were significantly higher in non-survivors compared to 
survivors (table 1). There was no significant difference in the number of male and female 
dogs between the two groups (table 1). 
 





Figure 1: Serum 25(OH)D concentrations in surviving and non-surviving dogs with a CE.
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 Survivors (n=26) Non-survivors 
(n=15) 
p value 
Age (months) 60.5 (33.0) 96.0 (48) 0.004* 
Calcium mmol/l 2.42 (0.26) 2.06 (0.57) 0.002* 
Albumin g/l 33.35 (7.95) 24.50 (13.9) 0.0007* 
CIBDAI 6 (3) 10 (5) 0.0022* 
25(OH)D ng/ml 24.90 (22.20) 4.3 (15.4)   0.0003*  
Male/female 18/8 9/6 0.733 
 
Table 1: Univariable analysis of clinical and biochemical variables in surviving and 
non-surviving dogs.  The data shows the median value for each variable and the 
interquartile range. * denotes statistical significance P<0.05 
 
A binary logistic regression model was performed to estimate the association between 
outcome and serum 25(OH)D concentrations conditional on a range of other candidate 
predictors. CIBDAI was not included in this model since it has previously been shown that 
this measure strongly correlates with serum 25(OH)D concentrations [5]. In this analysis 
intestinal inflammation scores were also included. These scores were available for 34 of the 
41 dogs. There was no significant difference in histopathology scores between dogs which 
died compared to ones which survived (p=0.06). There were 10 dogs with a score of less 
than 7, 10 dogs with a score of 7 or 8 and 14 dogs with a score of 9 or greater. The initial 
model included age, sex, histopathology score as a tertile, serum calcium, albumin and 
25(OH)D concentrations. After stepwise AIC selection, the optimal predictive final model 
Page | 53 
 
used serum 25(OH)D concentrations and age demonstrating that vitamin D status was an 
independent predictor of mortality in dogs with CE (table 2). Table 3 shows the 
consequences on model fit following the re-introduction of discarded predictors, 





Table 2: Results from the final binary logistic regression model of survivors versus 
non-survivors  
 
Table 3: Impact on model AIC following addition of dropped predictors. An increase 
in AIC represents a poorer parameter penalized model fit.  
 Odds ratio (95% CI) 
25(OH)D ng/ml 1.08 (1.02-1.18) 
Age months 0.97 (0.93-1.00) 
Added predictor AIC 




Histology tertile 40.31 
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3.4 Discussion 
The main finding of this study is that serum 25(OH)D concentrations were significantly 
lower at time of diagnosis in dogs which died or were euthanised as a result of a CE. This is 
an important finding since it is presently difficult to predict outcomes in dogs with a CE.  
Previous studies have shown that older age, hypoalbuminaemia and higher CIBDAI scores 
are predictive of a poorer outcome in dogs with a CE, findings which are further supported 
by this research [238-240]. This study, which demonstrates that serum 25(OH)D 
concentration at the point of diagnosis is a prognostic marker in dogs with a CE, will 
hopefully help provide additional valuable prognostic information to owners and veterinary 
surgeons managing dogs with a CE. Further work is needed to determine the optimal cut-off 
value for vitamin D as a prognostic marker.   
 
The mechanism(s) underlying a hypovitaminosis D state in canine CE is unknown. Reduced 
dietary intake of vitamin D in dogs with a CE could be an important cause of 
hypovitaminosis D, especially as dogs do not cutaneously produce vitamin D [16]. As low 
vitamin D status in dogs with a CE has been associated with a decreased appetite [5], this 
may, in part, explain the reduced serum 25(OH)D concentrations that are frequently 
observed in dogs with a CE. However, Gow et al have also found that dogs with a CE had 
lower 25(OH)D concentrations than hospitalised ill dogs with non-gastrointestinal illnesses, 
and many of these dogs also had reduced appetites [5]. Consequently, the influence of 
appetite on vitamin D status in dogs with a CE remains unclear.  
 
Circulating 25(OH)D is bound to vitamin D binding protein and albumin [241]. Enteric loss 
of albumin is regarded to be a significant problem in many dogs with a CE, notably in cases 
of protein losing enteropathies [242]. Consequently, loss of protein-bound vitamin D into the 
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gastrointestinal tract may account for the low vitamin D status in some dogs with a CE. This 
may explain previous work with has demonstrated a correlation between serum albumin 
concentrations and vitamin D status in dogs with a CE [5]. Similarly, albumin concentrations 
have also been shown to be a predictor of serum 25(OH)D concentration in humans and cats 
with IBD [10, 243]. Albumin can also decrease in inflammatory diseases as part of the acute 
phase response [244]. Studies have shown the systemic inflammatory response may be a 
confounding factor in determining vitamin D status [245]. This is supported by 
investigations which have shown that serum vitamin D binding proteins decreases in the face 
of acute inflammation and urinary excretion of vitamin D binding protein increases in the 
face of inflammation [148, 246]. Therefore, a reduction or loss of vitamin D from the plasma 
compartment due to redistribution of its binding proteins (serum albumin and vitamin D 
binding protein) may account for the decreases seen in 25(OH)D concentrations in acute 
inflammation and inflammatory diseases.  
 
Malabsorption may also contribute to low vitamin D status in human patients with Crohn’s 
disease and this could potentially influence serum 25(OH)D concentrations in dogs with a 
CE. However, whilst vitamin D absorption appears to be reduced in patients with Crohn’s 
disease compared to healthy controls, there seems to be substantial variation in absorption of 
vitamin D in these patients [247]. Further studies are needed in both people and dogs with 
CE to clarify the potential role of vitamin D malabsorption in driving a hypovitaminosis D 
state.  
 
Although hypovitaminosis D in CE has traditionally been considered to be a result of 
intestinal disease, there is growing evidence that hypovitaminosis D may contribute to the 
initiation of intestinal inflammation. Supporting evidence for a link between 
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hypovitaminosis D and CE comes from rodent models which have demonstrated that 
vitamin D receptor knock out (VDR−/−) mice are more susceptible to experimental forms of 
inflammatory bowel disease. For example, experimentally induced colitis in VDR−/− mice 
was significantly more severe compared to wild-type mice with chemically induced colitis 
[64, 248]. Furthermore, it has also been demonstrated that supplementing wild type mice 
with vitamin D can decrease the severity of gastrointestinal inflammation with chemically 
induced colitis [248]. Additionally, it has been shown that feeding mice a vitamin D 
restricted diet can predispose to IBD [249].  
 
Vitamin D has also been shown to profoundly modulate pro-inflammatory responses and to 
promote immunotolerance [250, 251]. Therefore, lack of vitamin D may drive abnormal 
inflammatory and immune processes. Subnormal vitamin D concentrations therefore may 
contribute to the inflammation seen in people with IBD and dogs with CE. Loss of tolerance 
to normally harmless bacterial and dietary antigens is hypothesised to be important for the 
development of canine CE [219]. Vitamin D may be important in regulating the immune 
response to commensal gut flora and maintaining normal bacterial populations. For example, 
dysbiosis was also reported in VDR−/− mice and mice Cyp27B1−/− mice [252] and dysbiosis 
may contribute to CE in dogs [253]. Therefore, the effects of vitamin D on the intestinal 
microbiota may also account for the association between serum 25(OH)D and inflammatory 
bowel disease. 
 
There is growing evidence linking vitamin D deficiency with disrupted intestinal mucosal 
barrier function. It has been proposed that altered epithelial barrier function, resulting in  
increased epithelial permeability, leads to increased exposure of the mucosal immune system 
to luminal antigens and that this may contribute to initiation and perpetuation of chronic 
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inflammation [254]. This hypothesis is supported by the observation that intestinal 
permeability is increased in people with naturally-occurring inflammatory bowel disease and 
their unaffected relatives [255]. Similar findings have been reported in dogs with naturally-
occurring CE where increased paracellular permeability has been demonstrated by lactulose 
to rhamnose absorption tests [256, 257]. In-vitro studies have demonstrated that calcitriol 
can markedly enhance tight junction protein expression [64]. The same study also 
demonstrated that VDR−/− mice were more susceptible to mucosal injury than wild type 
mice.   
 
A feature of inflammatory bowel disease is excessive intestinal cell apoptosis [258, 259].  It 
has recently been demonstrated that intestinal epithelial vitamin D receptor signalling 
inhibits experimental colitis and targeted expression of VDR in intestinal epithelial cells of 
mice protected them from experimental forms of colitis [260]. These results demonstrate that 
gut epithelial VDR signalling inhibits colitis by protecting the mucosal epithelial barrier. 
The same group demonstrated that reconstitution of VDR−/− intestinal epithelial cells with 
VDR transgenes protected VDR−/− mice from severe colitis and death by reducing intestinal 
epithelial cell apoptosis [260]. As these VDR−/− mice have a hyper-responsive immune 
system, the results indicated that intestinal VDR signalling has protective effects in IBD.  
Treating mice with chemically induced colitis with vitamin D analogues also appears to 
reduce intestinal epithelial cell apoptosis [261].  Therefore, vitamin D status may be 
associated with IBD in man and CE in dogs due to its effects on altered barrier function.  
 
Culture of colon cancer cells with tumour necrosis factor α (TNF-α) has been shown to 
suppress VDR and concurrently upregulate mircoRNA-346 (miR-346). In turn miR-346 
inhibits VDR expression [262]. These results indicate that during mucosal inflammation 
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VDR expression is down-regulated. The loss of mucosal VDR then results in a loss of the 
mucosal epithelial barrier integrity, further driving mucosal inflammation. Research is 
required to investigate whether similar changes in VDR expression occur in dogs with CEs. 
It is speculated that as vitamin D can induce VDR expression [263] and suppresses TNF-α 
[60, 264], treatment with vitamin D analogues may help prevent intestinal epithelial cell 
apoptosis and ameliorate the clinical signs associated with inflammatory bowel disease 
[264]. A reduction in intestinal epithelial cell VDR expression has been reported in naturally 
occurring IBD [260, 261].  
 
It is currently unclear if supplementing patients diagnosed with IBD with vitamin D 
improves patient outcomes. A recent meta-analysis of animal and human trials concluded 
that whilst many studies reported an improvement in IBD related symptoms or pathology 
after vitamin D supplementation, there is insufficient evidence to currently recommend 
vitamin D treatment for human cases of inflammatory bowel disease [265]. Therefore further 
research is needed into the potential role of vitamin D in the management of these diseases. 
In addition there is evidence to suggest that the hypovitaminosis D seen in people with 
inflammatory bowel disease will correct when the disease is managed independent of 
supplementation with exogenous vitamin D, suggesting that low vitamin D concentrations in 
IBD may be a consequence rather than the cause of IBD [266]. Studies are required in dogs 
to assess if supplementation with vitamin D or vitamin D analogues is beneficial in dogs 
with a CE. 
 
There are some limitations in this study. Firstly, there was no standardisation in treatment 
regimens which the dogs received before or after diagnosis of CE. This is a result of the 
retrospective nature of the study design. Some medications can influence vitamin D 
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metabolism in humans. However, it is unclear whether many commonly used drugs can 
influence vitamin D metabolism in dogs. For example, it has previously been shown that 
glucocorticoids do not alter vitamin D metabolism in dogs [182].  In light of paucity of 
information on how drugs influence vitamin D homeostasis it was elected to take an 
unbiased approach of not excluding any cases based on previous medical therapy. 
Additionally, differences in treatments may have affected outcomes in the dogs in this study 
independently of vitamin D status.  Another limitation of this study was that the results of 
faecal parasitology were missing from 5 of the dogs recruited for this study. Undetected 
parasite infections may have influenced the results of the variables measured for this study. 
However, it is unlikely that this has a major impact on test results as within this hospital 
population dogs are almost invariably prophylactically treated with appropriate worming 
medication especially prior to referral for investigation of gastrointestinal disorders. The 
observational nature of the study is another limitation, as it prevents conclusions being 
drawn as to whether low serum vitamin D concentrations are a cause rather than a 
consequence of vitamin D deficiency.  
 
3.5 Conclusion 
In summary, this study demonstrates that serum 25(OH)D concentrations are predictive of 
clinical outcome in dogs with CE. Although, causality cannot be inferred from these results, 
the finding that low serum 25(OH)D concentrations are negatively correlated with outcome 
highlights the need to further examine the relationship between vitamin D homeostasis and 
the risk of developing a CE and the effect of vitamin D status on outcome in dogs with a CE. 
The results of this study support the initiation of randomised placebo controlled studies 
utilising vitamin D supplementation in order to address these questions. 
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CHAPTER 4 
Vitamin D status and markers of inflammation in dogs with chronic enteropathies  
 
4.1 Background 
There is a growing body of evidence that vitamin D status is negatively associated with 
markers of inflammation (including circulating pro-inflammatory cytokines and acute phase 
proteins) in a number of diseases including obesity [267, 268], inflammatory polyarthritis 
[269], diabetes mellitus [270], autoimmune diseases [66, 271], inflammatory bowel disease 
[272, 273] and human immunodeficiency virus [274].  Furthermore, low vitamin D status 
has been associated with increased markers of inflammation in healthy humans [275-277].   
  
The reasons why low vitamin D status is negatively associated with inflammation are 
unclear, but are likely to be related to the role vitamin D plays in influencing immune 
responses. The vitamin D receptor (VDR) is found on most types of immune cells including: 
macrophages, dendritic cells, T-lymphocytes and B-lymphocytes [189]. Vitamin D can 
reduce inflammation by inhibiting the proliferation of immune effector cells and the 
production of inflammatory cytokines while enhancing production of anti-inflammatory 
cytokines [42]. Vitamin D can also act promote immunotolerance by increase regulatory T-  
cell populations [278, 279]. Despite the anti-inflammatory functions of vitamin D, vitamin D 
is also known to enhance the innate immune response to bacteria, by increasing production 
of anti-microbial peptides such as cathelicidin [57-59].   
 
The role of vitamin D in modulating inflammatory responses has been investigated by 
studying the effects of vitamin D supplementation on markers of inflammation in people. In 
healthy adults with low serum 25(OH)D concentrations, vitamin D supplementation has 
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been shown to increase concentrations of both circulating pro and anti-inflammatory 
cytokines [280]. In ill patients, vitamin D administration appears to reduce some markers of 
inflammation in patients with early chronic kidney disease [281], end-stage renal disease 
[282], congestive heart failure [283], systemic lupus [284] and colorectal adenoma [285]. In 
addition markers of inflammation decreased in elderly women with vitamin D insufficiency 
in response to supplementation with a mega-dose of vitamin D3 [286]. However, it is 
important to bear in mind that many other studies investigating the effects of vitamin D 
supplementation on markers of inflammation have failed to demonstrate in –vivo anti-
inflammatory effects. For example, high dose vitamin D treatment appears not to result in a 
decrease in inflammatory markers in people with low vitamin D status diagnosed with: pre-
diabetes and type 1 diabetes [270, 287], hypertension [288] and urticaria [289]. Furthermore, 
increases in pro-inflammatory cytokines were documented in patients with osteoporosis after 
vitamin D supplements were administered [290]. There are many potential explanations for 
why the results of different studies reported differing effects of vitamin D supplementation 
on markers of inflammation. These include: differences in the duration for which vitamin D 
supplementation was given, the type of vitamin D used for supplementation and the effects 
of various diseases. In addition, observational studies have demonstrated an U-shaped 
association between 25(OH)D and CRP concentrations, which indicates that higher 
25(OH)D concentrations may also be related to pro-inflammatory states [291, 292]. Benefits 
of vitamin D supplementation may therefore only be seen in patients with overt vitamin D 
deficiency and excessive supplementation may be detrimental.   
 
The relationship between vitamin D status and inflammation is poorly understood in dogs. 
Serum 25(OH)D concentrations are commonly reduced in a number of inflammatory 
diseases in dogs including congestive heart failure [3], spirocercosis [4], protein losing 
enteropathy [5, 6] and renal disease [7].  Low vitamin D status has been negatively 
associated with CRP in dogs with haemoabdomens [8]. However, other studies have 
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reported a positive association between vitamin D and CRP concentrations in racing sled 
dog [293]. Further work is needed to address the relationship between vitamin D and 
inflammation in dogs. 
 
Dogs with CE represent a spontaneous model in which to explore the relationship between 
vitamin D status and inflammation. It has been previously demonstrated that dogs with a CE 
can have a range of serum vitamin D concentrations, ranging from profound deficiency to 
sufficiency [5, 6].  This thesis has also shown in chapter three that serum vitamin D 
concentrations are predictive of clinical outcomes in dogs with CE, yet the relationship 
between 25(OH)D concentrations and inflammation in dogs with CE is poorly understood. A 
number of markers of systemic inflammation, including serum cytokines and leukocyte 
profiles can measured in dogs [294]. In addition the WSAVA gastrointestinal histopathology 
scoring system for endoscopic biopsies [237] provides a standardised means by which the 
extent of inflammation within gastrointestinal biopsies can be assessed. 
 
Chronic enteropathies are commonly diagnosed in dogs. Like IBD in man, CE represents a 
range of conditions associated with gastrointestinal inflammation. Again, similar to humans, 
hypovitaminosis D is a common clinical finding in dogs with CE [5, 6]. Unlike people, dogs 
do not produce vitamin D cutaneously and most are fed commercial diets containing 
relatively standard amounts of vitamin D. This limits the number of variables which 
influence vitamin D status, making dogs an attractive spontaneous disease model to study 
the relationship between systemic and gastrointestinal inflammation and serum 25(OH)D 
concentrations. This is of particular interest because although low vitamin D status is 
commonly reported in patients with IBD [221-224], the relationship between vitamin D 
status and IBD associated inflammation in human patients is not yet well defined.  
Investigators have assessed the link between the incidence of sub-optimal vitamin D 
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concentrations and increased markers of local and systemic inflammation in patients with 
IBD. The results of these studies are conflicting. For example, changes in markers of 
systemic inflammation such as CRP, fibrinogen, white blood cell count, platelet count, TNF-
α and erythrocyte sedimentation rate appear to be unrelated to vitamin D status in patients 
with IBD [222, 295, 296].  In contrast, faecal markers of gastrointestinal inflammation have 
been shown to be increased in patients with hypovitaminosis D and IBD [273, 296]. 
Furthermore, vitamin D insufficiency has also been associated with reduced concentrations 
of the anti-inflammatory cytokine IL-10 in patients with ulcerative colitis, suggesting that 
poor vitamin D status may be linked to reduced anti-inflammatory capacity in this group 
[295]. Ongoing work is needed to define the role of vitamin D in the initiation and 
perpetuation of gastrointestinal inflammation. Dogs may provide an attractive model in 
which this relationship may be studied. 
 
Hypothesis 
The study hypothesis was that vitamin D status would negatively correlate with markers of 
systemic and intestinal inflammation in dogs with CE.  
 
Objectives 
The aim of this investigation was to assess the association between serum vitamin D status 
and inflammation in dogs with CE by measuring 25(OH)D concentrations alongside: 
 
 Whole blood neutrophil counts, monocytes counts, lymphocyte counts and 
eosinophil counts.  
 Pro-inflammatory cytokines, IL-2, IL-6, IL-8 and TNF-α 
 Intestinal inflammation scores as a marker of local gastrointestinal inflammation. 
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The study also aimed to determine if serum 25(OH)D concentrations correlated to a specific 
‘inflammatory signature’ that could describe the changes in inflammatory markers seen in 
dogs with a CE. 
 
4.2 Material and Methods 
The records of dogs referred to the Hospital for Small Animals, Royal Dick School of 
Veterinary Studies for investigation of chronic gastrointestinal disease (more than three 
weeks in duration) were retrospectively reviewed. Dogs were considered eligible for 
inclusion in the study if they had presenting clinical signs consistent with a CE which 
included any of the following: vomiting, diarrhoea, increased borborygmi, abdominal pain, 
increased or decreased appetite and weight loss. All dogs were considered eligible if they 
had histopathological evidence of inflammation within the small or large intestines and if 
there were no clinically significant abnormalities detected on haematology, biochemistry or 
abdominal ultrasonography. In addition the faeces of all dogs were negative for both 
helminth and giardia infections. Biochemistry variables were measured on an ILab650 
biochemistry analyser, (Diamond Diagnostics, USA). The area of the intestinal tract which 
was biopsied (duodenum or duodenum and colon) was determined based on presenting 
clinical signs and by the primary clinician managing the case. A diagnosis of CE was made 
if there was histological evidence of intestinal inflammation and no clear underlying 
aetiology was diagnosed. For inclusion, residual stored serum samples were required for 
retrospective assessment of 25(OH)D status. 
 
 
Vitamin D analysis 
Serum samples retained for 25(OH)D measurement were frozen after being used for routine 
biochemical analysis. Serum was stored at –70°C before being sent to the laboratory for 
analysis on dry ice. Serum concentrations of 25(OH)D were measured as previously 
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described in detail [234, 235]. Samples were extracted using acetonitrile and applied to C18 
Silica Sep-paks. Separation of metabolites was by straight phase high performance liquid 
chromatography (HPLC) (Waters Associates, Milford, MA, USA) using a Hewlett-Packard 
Zorbax-Sil Column (Hichrom, Reading, UK) eluted with hexane:propan-2-ol:methanol 
(92:4:4). Serum 25(OH)D2 and 25(OH)D3 were measured separately by application to a 
second Zorbax-Sil Column eluted with hexane:propan-2-ol (98:2) and quantified by 
ultraviolet absorbance at 265 nm and corrected for recovery (sensitivity 5nmol/L, intra- and 
inter-assay coefficients of variation 3·0% and 4·2%, respectively) [236]. This Supraregional 
Assay Service laboratory is accredited by CPA UK (CPA number 0865) and has been 
certified as proficient by the international vitamin D Quality Assurance Scheme (DEQAS). 




Canine pro-inflammatory cytokines (IL-2, IL-6, IL-8 and TNF-α) were measured from 
serum samples using a multiplex electrochemiluminescence immunoassay system (Meso 
Scale Discovery; MSD) as previously described [294]. Assay diluent (25μL) was added to 
all wells, plates sealed and incubated for 30 minutes at room temperature on an orbital 
shaker (600 rpm). Samples and standards, diluted in assay diluent, were added at 25μL per 
well. Plates were again sealed and incubated for a further 2 hours at room temperature with 
shaking. At the end of the incubation period, wells were washed three times with 200μL/well 
phosphate-buffered saline (PBS), supplemented with 0.05% Tween 20 (Sigma–Aldrich) for 
30 seconds, and then discarded. Detection antibody was added at 25μL per well, plates 
sealed and incubated for a further 1 hour at room temperature with shaking. Plates were 
washed three times and 150μL of MSD Read Buffer added to each well, then 
electrochemiluminescence was measured using the MSD Sector Imager 2400 plate reader. 
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Histopathology 
Where available, slides of the original duodenal biopsies were reviewed by a single 
veterinary pathologist. A qualitative scoring system (WSAVA Standards for the Diagnosis 
of Gastrointestinal Inflammation in Endoscopic Biopsy Samples) [237] was used to assess 
the degree of inflammation. The template for this system assesses the following histological 
changes: (villous stunting, epithelial injury, crypt distension, lacteal dilatation, and mucosal 
fibrosis) and inflammatory infiltrates (intraepithelial lymphocytes, lamina propria 
lymphocytes and plasma cells, lamina propria eosinophils, and lamina propria neutrophils). 
The changes were graded as normal (0), mild (1), moderate (2) or severe (3). The sums of all 
these parameters were added together to determine an intestine inflammatory score which 




Initially statistical analysis was performed using GraphPad Prism version 6 (GraphPad 
software, La Jolla, CA). A Spearman’s rank coefficient was used to investigate potential 
correlations between serum 25(OH)D concentrations and intestinal inflammation scores, 
total white blood cell count, neutrophil, lymphocyte, monocyte and eosinophil 
concentrations and serum cytokines. A P value of <0.05 was considered to be statically 
significant. In order to investigate the relationship between multiple inflammatory markers 
and serum 25(OH)D concentrations, individual variables were examined using histograms 
and parameters which were not normally distributed (Anderson-Darling test) were 
transformed. Log10 transformation was undertaken except for square root transformation of 
eosinophil numbers since some eosinophil numbers were zero. The relationship between 
age, sex and 25(OH)D was examined using scatter plots and a linear regression model. The 
relationship between 25(OH)D and inflammatory markers was investigated using linear 
regression models. Age and sex were included in initial models in order to examine for any 
Page | 67 
 
confounding effects. Final models were selected by removing potential confounders if their 
removal did not worsen model fit as assessed by the Akaike information criterion (AIC, a 
penalty parameter penalised measure of model fit). As one of the study aims was to examine 
if 25(OH)D concentrations correlated to an inflammatory signature, medoid based 
partitioning was used to assign haematology parameters to three clusters. Three clusters was 
chosen on the basis of a consensus of results from 30 cluster count algorithms [297]. These 
clusters were identified independently of 25(OH)D concentrations. A Kruskal Wallis test 
was used to determine if there was a difference in 25(OH)D concentrations between the 
three clusters [298]. Tukey and Kramer posthoc test for pairwise comparisons were then 
used to identify which clusters differed. Data was collected using Excel and analysed using 





Thirty-nine dogs with a diagnosis of a CE were enrolled.  Breeds enrolled included; Boxer 
(9), cross breed (5),  Caviller King Charles Spaniel (2), Labrador (2), Lurcher (2), Springer 
Spaniel (2), Staffordshire Bull Terrier (2) and one of each of the following breeds: Border 
Collie, Border Terrier, Cocker Spaniel, Douge De Bordeaux, German Short Haired Pointer, 
Greyhound, Hungarian Vizsla, Irish Setter, Italian Greyhound, Pyrenees Mountain Dog, 
Shar pei, Shetland Sheep dog, Toy poodle, Yorkshire Terrier and a West Highland White 
Terrier. The age range of dogs included was 6 to 136 months (median 65 months). 
Haematology, biochemistry, faecal parasitology and abdominal ultrasonography did not 
reveal any significant clinical abnormalities in any of the 39 dogs that was not attributed to 
CE. Sixteen dogs underwent upper endoscopy and 23 dogs had both upper and lower 
endoscopy.  Thirty-two dogs had duodenal biopsy samples which were available for 
histological review by a veterinary pathologist who was blinded to the clinical history, 
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cytokine results and vitamin D status of the dogs. Other samples could not be retrieved from 
achieved stores. Cytokine analysis was available in 23 cases. 
 
Age and sex were not predictive of serum 25(OH)D concentrations in a linear regression 
model. The relationships between serum 25(OH)D concentrations and haematology, 
intestinal inflammation score and serum cytokine results are shown in figure 1. Numbers of 
neutrophils and monocytes, intestinal inflammation score and serum IL-2 and IL-8 
concentrations were negatively associated with 25(OH)D concentrations (table 1). Three 
clusters were identified in the haematology data (figures 2 and 3). There was a significant 
difference in 25(OH)D concentrations between the three clusters (p=0.009). Post-test 




Table 1:  Results of logistic regression model of inflammatory parameters on serum  
25(OH)D concentrations  *denotes statistical significance P<0.05
Variable 
 
Co-efficient (SE) P value 
Neutrophil number (log10) -0.011 (0.0026) 0.0001 * 
Monocyte number (log10) -0.016 (0.0039) 0.0002 * 
Eosinophil number (sqrt) 0.008 (0.0044) 0.092 
Lymphocyte number (log10) 0.005 (0.0035) 0.156 
Duodenal histopathology score (log10) -0.012 (0.0041) 0.006 * 
IL-2 (log10) -0.015 (0.0074) 0.048 * 
IL-6 (log10) -0.011 (0.0062) 0.086 
IL-8 (log10) -0.018 (0.0064) 0.013 * 
TNF-α (log10) -0.014 (0.0070) 0.061 
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Figure 1: Relationship between haematology, serum cytokines and duodenal inflammatory score and serum 25(OH)D concentrations 





Figure 2: Box and whisker plot of serum 25(OH)D concentrations by cluster. The box extends from 25% to 75% percentile with the median 
and the whiskers extend to limits of the data.  
Serum 25(OH)D ng/ml 




Figure 3: Pair-wise scatter plot of number of neutrophils (neut), monocytes (mono), eosinophils (eosino) and lymphocytes (lymph) labelled by 
cluster (red cluster 1, green cluster 2, and blue cluster 3). Values on x and y axis denote cell concentrations x109/l. 
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4.4 Discussion 
The central finding of this study is that serum 25(OH)D concentrations negatively correlate 
with systemic markers of inflammation in regards to neutrophil and monocyte numbers, 
serum IL-2 and IL-8 concentrations and local inflammation as measured by duodenal 
histopathology scores.  Linear regression and medoid based partitioning analysis 
demonstrated that dogs with low vitamin D status had an inflammatory signature consisting 
of high neutrophil and monocyte numbers and low lymphocyte numbers. A typical stress 
leukogram in dogs consists of neutrophilia, monocytosis and lymphopenia and similar 
changes can also be seen with an inflammatory leukogram. These results demonstrate that 
lower serum vitamin D status is seen associated with increased numbers of neutrophils, 
monocytosis and lymphopenia. These changes can be seen in a number of inflammatory 
conditions and are not-specific to dogs with a CE, however they provide evidence of an 
association between reduced serum 25(OH)D concentrations and systemic inflammation in 
this population of dogs.  
 
The results of this study also show that IL-2 and IL-8 concentrations are increased in the 
serum of dogs with CE and lower 25(OH)D concentrations. Cell culture models indicate that 
the pro-inflammatory cytokine, IL-2 is under direct transcriptional regulation by calcitriol 
and that calcitriol decreases IL-2 production [300]. Vitamin D supplementation has been 
associated with decrease in circulating IL-2 concentrations in children with atopy [301].  As 
seen in the dogs in this study, increased IL-2 concentrations have been reported in vitamin D 
insufficient adults [302]. Serum IL-8 were also increased in this population of dogs with a 
CE. In human IBD IL-8 is an important inflammatory mediator, which plays a role in the 
initiation and maintenance of IBD by recruiting neutrophils into inflamed tissues [303]. 
Increases in serum IL-8 concentrations have also been reported in human patients with IBD 
[304]. It is also interesting that vitamin D has been shown to exert anti-inflammatory effects 
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by decreasing IL-8 production in intestinal cell cultures [305]. The role of these cytokines in 
canine CE and the effects of vitamin D status on their expression in dogs is worthy of further 
investigation. 
 
The results of this study indicate that low serum vitamin D concentrations are associated 
with more severe inflammation as assessed by intestinal inflammation scores. This provides 
evidence of an association between local inflammation and reduced vitamin D 
concentrations. Although faecal markers of local gastrointestinal inflammation have been 
associated with low vitamin D status in people [273, 296], this is the first time that 
histopathological scores have been associated with reduced vitamin D concentrations.  
 
It is unclear if the low 25(OH)D concentrations observed in inflammatory diseases are 
causally related to inflammation or if lower vitamin D status occur as a consequence of the 
inflammatory process itself. Serum 25(OH)D concentrations have been shown to decrease 
following elective surgical procedures in human patients, coupled with increases in 
inflammatory markers such as CRP [148]. This suggests that vitamin D is a negative acute 
phase reactant [148]. Serum 25(OH)D concentrations also fall rapidly in other inflammatory 
conditions such as acute pancreatitis [306]. Increases in pro-inflammatory cytokines have 
been proposed to be the cause of decreases in serum 25(OH)D seen in acute inflammation. 
For example, changes in serum 25(OH)D over several weeks corresponded with increases in 
serum pro-inflammatory cytokines including: TNF-α, Interferon-gamma (IFN-γ), IL-1β, 
Granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-6 concentrations in 
patients undergoing knee arthroplasty [149]. In addition, changes in vitamin D status 
following inflammation may relate to changes in vitamin D binding proteins. For example, 
serum vitamin D binding protein decreases in the face of acute inflammation [246]. 
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However, not all studies looking at illness events associated with acute inflammation have 
demonstrated decreases in serum 25(OH)D concentrations. For example, acute myocardial 
infarction is associated with increased markers of inflammation but serum 25(OH)D 
concentrations remained unaltered following infarction [307]. Studies in patients with 
tuberculosis have also demonstrated decreases in vitamin D are not seen during acute phase 
responses [308].  
 
Hypovitaminosis D may contribute to the initiation of intestinal inflammation. Studies using 
experimental models of inflammatory bowel disease have demonstrated that vitamin D can 
have an anti-inflammatory effect. For example, in a murine model of IBD, calcitriol was 
shown to inhibit a number of genes involved in regulating TNF-α production and signalling 
[309]. Furthermore, VDR knockout mice produce significantly higher cytokine 
concentrations in response to chemically induced gastrointestinal inflammation than wild 
type mice [248]. These findings suggest that vitamin D is important in regulating 
gastrointestinal inflammation. However, it is not clear whether these findings can be 
extrapolated directly to patients with IBD. For example markers of inflammation including: 
CRP, erythrocyte sedimentation rate (ESR), TNF-α, IL-17, IL-10 and vascular endothelial 
growth factor concentrations did not change following vitamin D3 supplementation in people 
with IBD [231]. Therefore, further work is needed to determine the role of vitamin D in the 
treatment of inflammatory bowel disease in people and dogs.  
 
Recent investigations also demonstrate that intestinal epithelial vitamin D receptor is 
important for the regulation of mucosal inflammation by maintaining the integrity of the 
intestinal mucosal barrier [310] and VDR signalling can inhibit intestinal inflammation 
[260]. However, expression of the VDR by intestinal epithelial cells is down-regulated by 
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mucosal pro-inflammatory cytokines [262, 310].  These results suggest that inflammation 
interferes with the immunomodulatory effects of vitamin D. 
 
There are a number of limitations in this study. The retrospective nature of this study made it 
impossible to standardise the drugs and dietary treatments dogs received prior to referral for 
assessment and diagnosis of their CE. These treatments may have affected the changes in 
inflammation markers seen and may have altered serum 25(OH)D concentrations. It would 
be also be desirable to have assessed other markers of local gastrointestinal inflammation in 
dogs such as faecal calprotectin [311]. Measurement of serum CRP concentrations may have 
also proved a useful assessment of systemic inflammation as CRP can detect inflammation 
that is unaccompanied by changes in leukocyte counts [312]. In addition, serum cytokine 
concentrations and gastrointestinal histology slides were not available from all dogs as some 
archived samples were missing.  
 
4.5 Conclusion 
In summary, this study has shown that serum 25(OH)D concentrations are inversely 
associated with markers of systemic inflammation in dogs and with the severity of 
inflammatory changes seen in histopathology samples. The results of this study indicate that 
clinical trials supplementing dogs with chronic enteropathies with vitamin D could provide a 









Investigating the relationship between feline immunodeficiency virus infection and 
vitamin D status 
 
5.1 Introduction 
Feline immunodeficiency virus (FIV) is a retrovirus of domestic cats and other felidae which 
belongs to the lentivirus genus [313]. Transmission primarily occurs by horizontal spread 
between adult cats through bite wounds.  Risk factors for infection include cats with outdoor 
access and cats with aggressive behaviour [314]. Once FIV infection has been acquired most 
cats experience a transient period of viraemia accompanied by pyrexia, lymphadenopathy, 
lethargy, anorexia and leukopenia [313-315].  After several weeks the viraemia subsides and 
cats often enter a prolonged asymptomatic phase of infection lasting many years. During this 
clinically asymptomatic phase there is a progressive decline in CD4+ T-lymphocytes [316]. 
Some infected cats will remain asymptomatic despite this decline in CD4+ T-cells; however, 
in other cats, the decline in CD4+ T-cells and resulting immune dysfunction leads to an 
increased susceptibility to infections, immune-mediated diseases and neoplasia [314]. 
 
Feline immunodeficiency virus shares many morphological and pathophysiological features 
with the human lentivirus, human immunodeficiency virus (HIV). Like HIV, FIV is 
characterised by tropism for lymphocytes, macrophages and cells of the central nervous 
system [317, 318]. In the host species, infection with each virus leads to a progressive 
acquired immunodeficiency syndrome. The immune dysfunction seen as a result of HIV and 
FIV infections includes cytokine dysregulation, inappropriate activation of immune 
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regulatory cells and T-cell anergy and apoptosis [319]. Overall, these conditions are 
associated with a pro-inflammatory state and an increase in plasma cell activity with non-
specific immunoglobulin production. 
 
A large number of studies have investigated the relationship between serum 25(OH)D 
concentrations and the incidence, progression and morbidity associated with HIV infection. 
Cross sectional studies have documented a high incidence of low vitamin D status in patients 
infected with HIV [77, 78]. Sub-optimal vitamin D status has been associated with lower 
CD4+ T-cell counts, HIV progression and AIDs related morbidity and survival [82, 84, 320, 
321]. One large scale study has also identified vitamin D deficiency as an independent risk 
factor for all-cause mortality in HIV-positive patients [322]. 
 
The mechanistic link between vitamin D deficiency and HIV progression and AIDS related 
morbidity and survival may be via the marked immunomodulatory properties of calcitriol. 
The roles of vitamin D within the immune system include; down-regulation of pro-
inflammatory cytokines, suppression of T-cell activation, shifting of T-cell responses from a 
Th1 to Th2 type response, regulation of monocyte chemotaxis, macrophage function and 
dendritic cell phenotypes and regulation of the production of antimicrobial and antiviral 
peptides [189, 323]. Given the known immunomodulatory function of vitamin D, it is 
possible that a combination of HIV infection and insufficient vitamin D could be additive in 
promoting immune dysfunction in patients infected with HIV. Due to the increasing 
evidence of the immunomodulatory effects of vitamin D and the association between sub-
normal vitamin D levels and increased mortality, there is growing interest in the benefit of 
vitamin D supplementation in HIV-positive patients [77]. 
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Hypothesis 
Given the similarities between HIV and FIV infection, the study hypothesis is that the 
vitamin D status of FIV infected cats would be significantly lower than the vitamin D status 
of healthy control cats.  
 
Objectives 
The aim of this retrospective study was to measure and compare serum 25(OH)D 
concentrations in: 
 Cats infected with FIV, 
 Healthy cats  
 A general population of hospitalised ill cats 
 
5.2 Material and Methods 
Study Population 
The study was undertaken using residual serum samples from cats treated at the Hospital for 
Small Animals, Royal Dick School for Veterinary Studies, University of Edinburgh and 
clinical samples submitted to Langford Veterinary Services, University of Bristol for 
determination of FIV status. 
 
Healthy control cats were defined as healthy based on history, clinical examination findings, 
routine haematology and serum biochemistry. Cats enrolled in this group were blood 
sampled for the primary clinical purposes of assessment of PCV, biochemistry, FIV status 
and feline leukaemia virus (FeLV) status prior to blood donation or for routine FIV/FeLV 
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testing prior to re-homing. Feline immunodeficiency virus and FeLV status was tested using 
enzyme-linked immunosorbent assay (ELISA) (SNAP® FIV/FeLV Combo Test, IDEXX 
Corp., Portland, Maine, USA). 
 
The hospitalised ill cats were consecutively recruited from cats admitted to the Hospital for 
Small Animals, Royal Dick School for Veterinary Studies, University of Edinburgh. Cats 
were included in this group if they had history and clinical examination findings indicating 
that diagnostic interventions were warranted. Signalment, history, recent drug 
administration, haematology results, serum biochemistry results and final diagnosis were 
recorded for each case. Feline immunodeficiency virus status was tested  using a (SNAP® 
FIV/FeLV Combo Test; or CITE Combo FIV-FeLV, Agritech Systems, Portland, Maine, 
USA; or Speed® FIV, Virbac Animal Health, La Seyne sur Mer, France). Cats which tested 
positive for FIV were excluded from the hospitalised sick group.  
 
Samples retrieved for inclusion in the FIV-infected group were obtained from residual 
samples submitted to Langford Veterinary Services, University of Bristol to establish FIV 
status. Each of the cats recruited tested positive for FIV by ELISA (PetCheck® FIV antigen 
ELISA, IDEXX Corp.) 
 
Vitamin D Measurement 
Following handling of blood samples for routine diagnostic procedures, serum samples were 
stored at -20°C until 25(OH)D levels were measured. Samples were sent frozen in batches 
and 25(OH)D levels measured by high-performance liquid chromatography (HPLC). 
Briefly, samples were extracted using acetonitrile and applied to C18 Silica Sep-paks 
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(Waters Associates, Milford, MA, USA). Separation of metabolites was by straight phase 
HPLC (Waters Associates) using a Hewlett-Packard Zorbax-Sil Column (Hichrom, Reading, 
UK) eluted with hexane:propan-2-ol:methanol (92:4:4). Serum concentrations of the two 
major vitamers of 25(OH)D, 25(OH)D2 (ergocalciferol) and 25(OH)D3 (cholecalciferol), 
were measured separately by application to a second Zorbax-Sil Column eluted with 
hexane:propan-2-ol (98:2) and quantified by UV absorbance at 265 nm and corrected for 
recovery (sensitivity 5 nmol/L, intra- and inter-assay coefficients of variation 3.0 % and 4.2 
%, respectively). Vitamer concentrations were combined and results expressed as total 
25(OH)D as described previously [324]. The assay laboratory is accredited to ISO 
9001:2008 and ISO 13485:2003. 
 
Statistical Analyses 
Serum 25(OH)D concentrations were compared between healthy cats, hospitalised ill cats 
and FIV-infected cats using a Kruskal-Wallis test with post-test Dunn’s multiple comparison 
tests. Statistical analysis was performed with the commercial software package GraphPad 
Prism 6 (GraphPad Software, La Jolia, CA, USA). P<0.05 was considered significant. 
 










The 20 cats in the healthy control group comprised of 11 domestic short-haired, 2 domestic 
long-haired, 2 British short hairs and 2 Maine Coon cats. Eleven were neutered males, 6 
were neutered females, two were entire males and one was an entire female. The ages of the 
cats in the healthy control group ranged from 2 to 11 years, with a median age of 5.5 years. 
 
The 39 cats in the hospitalised ill group comprised of 26 domestic short-haired, 5 domestic 
long-haired, 3 Maine Coon,  2 Bengal, 1 Burmese, 1 Norwegian Forest Cat and 1 Ragdoll 
cats. Twenty-four cats were neutered males, 2 were male entire and 13 were neutered 
females. Their ages ranged between 4 months and 18 years, with a median age of 8 years. 
The cats were diagnosed with a range of medical conditions including: aortic 
thromboembolism (1), biliary carcinoma (1) chronic kidney disease (3), congestive heart 
failure (2), diabetes mellitus (1), dysautonomia (1), feline infectious peritonitis 
(1),fibrosarcoma (1), idiopathic chylothorax (1), idiopathic feline lower urinary tract disease 
(3), idiopathic megaoesophagus (1) hepatic disease (1), herpes virus (1), hyperthyroidism 
(7), inflammatory bowel disease (2), gastrointestinal lymphoma (2), renal lymphoma (1), 
multicentric lymphoma (1), lymphadenopathy (1), myelodysplasia (1), oral squamous cell 
carcinoma (1), pyothorax (3), stomatitis (1) urolithiasis (1).  
There was no clinical data available for the 59 cats in the FIV-infected group. 
 
Serum 25(OH)D concentrations 
The median serum 25(OH)D concentration in the healthy cats was 44.7ng/ml (range 14.9-
61.0ng/ml). For the hospitalised ill cats the median 25(OH)D concentration was 30.9ng/ml 
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(range 7.1-82.40ng/ml). FIV infected cats had a median 25(OH)D concentration of 
32.10ng/ml (range 5.0-62.4ng/ml). 
 
Serum 25(OH)D concentrations were significantly different between healthy control cats, 
hospitalised ill cats and FIV-infected cats (p<0.05); (figure 1). There was a significant 
difference in 25(OH)D concentrations between healthy cats and FIV infected cats (p<0.05) 
and between healthy cats and hospitalised sick cats (p<0.05). There was no difference in the 
serum 25(OH)D concentrations between the hospitalised ill cats and the FIV infected cats.













Figure 1: Serum 25(OH)D concentrations in healthy cats, hospitalised ill cats and FIV infected cats
Study Group 
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5.4 Discussion 
The central finding of this study is that FIV-infected cats have significantly lower serum 
vitamin D concentrations than healthy cats. This observation is similar to the findings of 
numerous studies in humans which have documented lower serum levels of vitamin D in 
HIV-positive patients [78]. Despite the well documented association, the clinical relevancy 
of a low vitamin D status in patients with HIV is not fully understood. Since HIV is a 
disease of immune dysfunction and vitamin D is known to have immunomodulatory 
properties, several studies have investigated whether vitamin D influences the immune 
response of HIV-positive patients. As an intracellular virus, HIV replicates and evades the 
host immune response by down regulating cell mediated immune responses including 
autophagy by HIV-infected macrophages [325]. Physiological doses of vitamin D have been 
shown to trigger autophagy and therefore inhibit HIV replication [326]. Furthermore the 
addition of vitamin D antagonists decreases the inhibition of HIV-1 replication [326]. In 
addition vitamin D pre-treatment has also been shown in vitro to decrease HIV infection, 
suppress viral replication, increase monocyte chemotaxis and to improve the monocyte 
maturation defects seen in HIV-positive patients [327]. Vitamin D has also been shown to 
decrease the number of Mycobacterium avium bacteria in macrophages from HIV-positive 
patients but not in HIV-negative controls, suggesting vitamin D may improve macrophage 
functions in HIV-positive patients [328]. Despite the significant body of evidence that has 
shown that vitamin D can modulate the immune response in HIV patients, it is unclear 
whether vitamin D supplementation can reduce morbidity and mortality in HIV-positive 
patients.  
 
The second main finding of this study is that the vitamin D status of cats with FIV is not 
lower than FIV-negative ill cats which have been hospitalised with a range of conditions. It 
is unclear if low serum vitamin D concentrations are simply a non-specific change which 
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commonly occurs in ill cats or whether vitamin D status plays a physiological role in disease 
development and progression. A growing body of data in human medicine has shown that 
vitamin D concentrations are negatively associated with all-cause mortality and vitamin D 
supplementation may ameliorate morbidity [161, 216]. In chapter two this thesis also 
demonstrates that serum 25(OH)D are predictive of all-cause mortality in cats.  The presence 
of vitamin D receptors on immune cells combined with experimental evidence shows that 
vitamin D can markedly modulate the immune system may partly explain why vitamin D 
status appear to have such an important association with outcome in a number of diseases.  
 
There are several limitations in this study. Firstly, signalment and clinical data were missing 
from the FIV infected cohort. Although this limits the ability of this study to conclude 
whether reduced 25(OH)D concentrations are a direct consequence of FIV infection or due 
to co-morbid disease, the results do indicate that cats with FIV infections are not at any 
greater risk of having lower vitamin D status than FIV negative, hospitalised ill cats. The 
other limitation of the study is that different ELSIA tests were used to assess FIV status. In 
general in house tests for FIV have a similar specificities and sensitivities [329], making it 
unlikely that the use of different kits would adversely affect the validity of our results.  
 
The relationship between vitamin D status and both disease susceptibility and treatment 
outcomes warrants further prospective investigation in a well-defined population of ill cats. 
In addition, future studies which investigate serum vitamin D concentrations in clinically 
well and clinically ill FIV-infected cats would allow the association of secondary illnesses 
on vitamin D status to be assessed.  
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5.5 Conclusion 
In summary, this study has shown that FIV-infected cats have a significantly lower vitamin 
D status than healthy control cats. The vitamin D status of FIV-infected, hospitalised ill and 
healthy cats and the relationship between vitamin D status and long term prognosis in FIV-





















Thesis summary and conclusions 
 
In summary the findings of this thesis provide further information about the role of vitamin 
D in companion animal diseases. 
 
Firstly, serum 25(OH)D concentrations are predictive of short term all-cause mortality in a 
general hospital population of cats and also of mortality in dogs with a diagnosis of CE. This 
is important for a number of reasons. Prognostic markers are valuable in allowing veterinary 
surgeons to guide owners in decision making processes and also to highlight animals where 
closer monitoring or attention is beneficial. Currently it is extremely difficult to predict 
clinical outcomes in cats and dogs. In cats there are a very limited number of prognostic 
markers available, and the current methods previously reported include the Feline Acute 
Patient Physiologic and Laboratory Evaluation (Feline APPLE) Score [215]. This scoring 
system has been validated only for feline intensive care unit (ICU) patients and requires 
several clinical and diagnostic parameters to be assessed. A uni-variable measure such as 
serum 25(OH)D concentrations, applicable to a general population of ill cats, including 
those in ICU may provide a simpler and more readily usable predictor of mortality. A small 
number of prognostic markers have been reported for dogs with CEs, these include: older 
age, hypoalbuminaemia and higher CIBDAI scores [238]. Knowledge that vitamin D is 
associated with poor outcome provides further prognostic information. In addition, unlike 
the other prognostic markers associated with CE, serum 25(OH)D can potentially be 
improved with supplementation with parental or oral vitamin D analogues. Although the 
research in this thesis did not assess whether low serum vitamin D concentration are causally 
associated with poor outcomes in cats and dogs, it does highlight that randomised controlled 
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clinical trials with vitamin D supplementation merit consideration and may lead to potential 
therapeutic interventions.  
 
The results of this thesis also highlight that hypovitaminosis D is common in ill and 
hospitalised cats and dogs. The results from chapter five, which compares the serum 
25(OH)D concentrations of cats with FIV infections to a general population of hospitalised 
ill cats shows that although cats with FIV have lower 25(OH)D concentrations than healthy 
cats, the decrease in 25(OH)D is no greater than that seen a general population of ill cats.  
This is similar to the findings of  a study by Lalor et al which found, that although serum 
25(OH)D concentrations are lower in cats with mycobacterial infections when compared to 
healthy cats, they do not have lower serum 25(OH)D than a hospitalised ill control 
population [11]. However, in contrast other diseases may cause more profound decreases in 
serum 25(OH)D concentrations. For example Gow et al demonstrated that serum vitamin D 
concentrations were significantly lower in dogs with protein losing enteropathies compared 
to a hospitalised control population and dogs with CE not resulting in protein losing 
enteropathy [5]. Lalor et al also demonstrated that serum 25(OH)D concentrations were 
lower in cats with inflammatory bowel disease or gastrointestinal lymphoma than a general 
population of ill hospitalised cats [10]. Both Gow et al and Lalor et al demonstrated that low 
serum vitamin D concentrations were related to serum albumin concentrations. These results 
suggest some diseases have a more profound, disease specific effect on serum 25(OH)D 
concentrations. The effects on different disease processes on serum 25(OH)D concentrations 
are worthy of further study. 
 
The results from chapter four have sought to start to investigate the association between 
inflammation and serum 25(OH)D in companion animals. Previously limited work has been 
undertaken to address this question. Investigators have examined the relationship between 
serum 25(OH)D concentrations and markers of inflammation by looking at CRP 
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concentrations in dogs with a haemoabdomen [8] and in association with the effects of 
strenuous exercise [293]. The results of these investigations have however been conflicting. 
Our results suggest that low vitamin D concentrations are associated with markers of 
systemic and local inflammation in dogs with a CE. Of particular interest is that a specific 
‘inflammatory signature’ consisting of neutrophilia, monocytosis, and increased serum IL-2 
and IL-8 concentrations were seen in these dogs. The relationship between serum 25(OH)D 
concentrations and these inflammatory markers, highlights areas for research to determine if 
low serum 25(OH)D are a cause of consequence of inflammation. 
 
The final important finding from this work is that changes in serum 25(OH)D seen in cats 
and dogs are similar to those reported in ill people. This suggests that cat and dogs may 
provide a valuable alternative to rodent models in which the effects of vitamin D on health 
outcomes can be probed without the need to induce disease in otherwise healthy animals. 
These naturally models would be free from many of the confounding variables which make 
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Abstract
Vitamin D insufficiency, defined as low serum concentrations of the major circulating form of
vitamin D, 25 hydroxyvitamin D (25(OH)D), has been associated with the development of
numerous infectious, inflammatory, and neoplastic disorders in humans. In addition, vitamin
D insufficiency has been found to be predictive of mortality for many disorders. However, in-
terpretation of human studies is difficult since vitamin D status is influenced by many factors,
including diet, season, latitude, and exposure to UV radiation. In contrast, domesticated
cats do not produce vitamin D cutaneously, and most cats are fed a commercial diet con-
taining a relatively standard amount of vitamin D. Consequently, domesticated cats are an
attractive model system in which to examine the relationship between serum 25(OH)D and
health outcomes. The hypothesis of this study was that vitamin D status would predict short
term, all-cause mortality in domesticated cats. Serum concentrations of 25(OH)D, together
with a wide range of other clinical, hematological, and biochemical parameters, were mea-
sured in 99 consecutively hospitalised cats. Cats which died within 30 days of initial assess-
ment had significantly lower serum 25(OH)D concentrations than cats which survived. In a
linear regression model including 12 clinical variables, serum 25(OH)D concentration in the
lower tertile was significantly predictive of mortality. The odds ratio of mortality within 30
days was 8.27 (95% confidence interval 2.54-31.52) for cats with a serum 25(OH)D concen-
tration in the lower tertile. In conclusion, this study demonstrates that low serum 25(OH)D
concentration status is an independent predictor of short term mortality in cats.
Introduction
Vitamin D is traditionally known for its role in calcium homeostasis and bone metabolism.
However, it has been demonstrated that numerous types of cells express the vitamin D receptor
and it is now clear that the physiological roles of vitamin D extend beyond the maintenance of
skeletal health [1, 2]. Vitamin D insufficiency, which is typically assessed by measuring the
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major circulating form of vitamin D, 25 hydroxyvitamin D (25(OH)D), has been associated
with a number of disorders including hypertension [3], diabetes [4], cardiovascular diseases
[5], cancer [6], autoimmune conditions [7] and infectious diseases [8–10]. Furthermore, low
serum 25(OH)D concentrations have also been linked to all-cause mortality in the general
human population [11]. Meta-analyses have demonstrated that serum 25(OH) concentrations
are an important predictor of survival in people with a wide variety of illnesses [12–15].
However, interpretation of these studies is challenging. A large number of factors are
known to influence serum 25(OH)D concentrations in humans including ethnicity [16–18],
diet [18–20], seasonality [21], latitude and exposure to sunlight [22–24], obesity[25, 26], age
[27] and gender [28]. Consequently, exploring the relationship between serum 25(OH)D con-
centrations and all-cause mortality in a model system in which many of these confounding fac-
tors are avoided would be of significant interest. Furthermore, a model system which did not
require disease to be induced in otherwise healthy animals would allow the number of animals
used in scientific research to be reduced. We predict that client owned, domesticated cats
which developed spontaneous disease would be a suitable model in which to study the relation-
ship between vitamin D and all-cause mortality. Advantages of investigating the role of 25
(OH)D on health outcomes in cats include a more standard dietary intake of vitamin D since
almost all cats which attend our referral veterinary hospital eat a commercial diet which is sup-
plemented with a similar amount of vitamin D [29]. In addition, cats do not synthesize vitamin
D cutaneously meaning that serum 25(OH)D concentrations are not influenced by exposure to
UV radiation [30, 31].
Investigating the role of serum 25(OH)D concentrations and all-cause mortality in cats
would be of interest to veterinarians since it is presently difficult to accurately predict mortality
in hospitalised, ill cats. The identification of clinical measures which were predictive of mortali-
ty would be extremely helpful in providing much needed prognostic information to owners of
ill cats. The aim of this study was to investigate whether serum 25(OH)D concentrations was a
predictor of short term, all-cause mortality in hospitalised ill cats. We have recently demon-
strated that vitamin D metabolism is altered in dogs and cats with a wide range of infectious,
inflammatory and neoplastic conditions, highlighting the need to clarify the relationship be-
tween serum 25(OH)D concentrations and mortality [32–38]. We hypothesised that cats with
low serum 25(OH)D concentrations would have higher mortality at 30 days post admission
than cats which were vitamin D replete.
Material and Methods
Study Population
Consecutive cats examined at the Royal (Dick) School of Veterinary Studies, Hospital for Small
Animals were considered eligible for inclusion in the study. Informed consent for the use of re-
sidual clinical blood samples for research purposes was obtained at admission for each cat en-
rolled. Ethical approval for the study was obtained from the University of Edinburgh’s
Veterinary Ethical Review Committee.
Clinical records were reviewed for each cat enrolled. The age, sex and breed were recorded
for each cat. Survival data was obtained from clinical records or follow up telephone calls to cli-
ents and referral veterinary surgeons for each cat at day 30 post initial presentation. The follow-
ing clinical information was extracted for each patient: white blood cell count, packed cell
volume (PCV), serum albumin, serum creatinine, sodium concentrations, potassium concen-
trations, total calcium concentration and 25(OH)D concentrations. In addition, the appetite of
the cats was graded as normal or reduced. Haematology variables were measured on an
ADVIA(r) 2120i System with Autoslide (Siemens Medical Solutions Diagnostics Ltd
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California, USA). Biochemistry parameters (serum sodium, potassium, creatinine, albumin
and total calcium) concentrations were measured on an ILab650 biochemistry analyser, (Dia-
mond Diagnostics, USA).
Following handling of blood samples for routine diagnostic procedures, serum samples
were stored initially at -20°C and later moved to -70°C for longer term storage until 25(OH)D
concentrations were measured as a batch. Previous studies have indicated that 25(OH)D is sta-
ble when stored at -20°C [39]. Serum concentrations of 25(OH)D2 and 25(OH)D3 were deter-
mined by liquid chromatography tandem mass spectrophotometry (LC-MS/MS) using an
ABSciex 5500 tandem mass spectrophotometer (Warrington, UK) and the Chromsystems
(Munich, Germany) 25OHD kit for LC-MS/MS following the manufacturers’ instructions
(intra- and inter-assay CV 3.7% and 4.8% respectively). This Supraregional Assay Service labo-
ratory is accredited by CPA UK (CPA number 0865) and has been certified as proficient by the
international Vitamin D Quality Assurance Scheme (DEQAS). Total 25(OH)D is defined as
the sum of 25(OH)D2 and 25(OH)D3. The laboratory measuring the vitamin D metabolites
were blinded to clinical data from the enrolled cats. In addition, clinicians were not aware of 25
(OH)D results during the clinical management of the cats.
Statistical Analysis
Initially, we compared the 25(OH)D concentrations between cats which died within 30 days of
sampling to cats which survived by a Mann-Whitney U test. In order to investigate for the
presence of confounding variables we constructed a standard binary logistic regression model
of death by 30 days. We included a range of clinical and biochemical data including sex, age,
breed, total white blood cells, packed cell volume and serum concentrations of albumin, total
calcium, creatinine, sodium and potassium. We also included an assessment of appetite as a bi-
nary variable of normal or reduced. Initially we included 25(OH)D concentrations as a linear
predictor within the logistical regression model. We also categorised serum 25(OH)D concen-
tration into 3 categories based on 33% and 66% tertiles treating the variable as a three level fac-
tor and also as low versus middle and high categories combined. We used Akaike’s
information criteria (AIC—a parameter penalised measure of model fit) to stepwise select vari-
ables which were to be retained to identify a final model with minimum AIC (i.e. best parame-
ter penalised fit). P values for individual variables were calculated using Wald’s test. A p-value
of< 0.05 was considered to be evidence of statistical significance.
Results
Study Population
A total of 99 cats were recruited to the study. The median age of the cats was 96 months. There
were 3 entire male, 56 neutered males, 1 entire female and 39 neutered female cats. Breeds in-
cluded in the study were 62 Domestic Short Hairs, 8 Domestic Long Hairs, 6 Maine Coons, 5
Burmese, 3 Bengals, 2 Tomikense, 2 Siamese, 2 Ragdolls, 2 Burmese crosses, 2 Oriental Short
Hair, 1 Manx Cat, 1 British Short Hair, 1 Chinchilla, 1 Burmillia and 1 Abyssinian.
There was a significant difference between the 25(OH) D concentrations between cats
which were alive (n = 80) compared to cats which had died at 30 days (n = 19) (p = 0.0022, Fig
1). Using serum 25(OH) D concentrations as a linear predictor of survival within the logistic
regression model, none of the variables, including 25(OH)D concentration, were significant
predictors of mortality. Since several studies in humans have also shown a non-linear relation-
ship between vitamin D status and mortality [11, 40, 41], we investigated whether serum 25
(OH)D concentrations were a significant predictor of mortality when represented as a categori-
cal variable. We found that cats with a 25(OH)D concentration in the lower tertile had an
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increased risk of mortality compared to cats in the middle tertile reference category (Table 1).
There was no significant difference in survival between cats in the upper and middle tertile
(Table 1). The only other parameters which were associated with an increased risk of mortality
by 30 days were potassium concentration and a reduced appetite (Table 1).
Based on the results of the three tertile model and the epidemiological data which links low
vitamin D status to poor health outcomes [12], we combined the middle and upper tertile into
a single binary predictor in a third model. A serum 25(OH)D concentration in the lower tertile
remained predictive of 30 day mortality (Table 2). Again, we found that potassium concentra-
tion and a reduced appetite were the only other parameters included in the third model which
were predictive of survival (Table 2).
Discussion
The central finding of this study demonstrates that hospitalised ill cats with low serum 25(OH)
D concentrations were less likely to survive 30 days. Using a regression model which included
serum 25(OH)D concentrations as a linear variable, none of the 12 clinical, biochemical and
hematological parameters, including 25(OH)D concentrations, were predictive of mortality.
Fig 1. Box and whiskers plot of serum concentrations of 25(OH)D in nmol/l in cats which died or were
alive at 30 days post admission. Box extends from 25th-75th percentiles with solid line representing the
median value. Whiskers extend to 5th-95th percentiles.
doi:10.1371/journal.pone.0125997.g001
Table 1. Results of logistic regression model including serum 25(OH)D concentration as three tertile
categorical variable.
Variable Odds ratio (95% CI) P value
Potassium 4.23 (1.36–14.59) 0.0153
Reduced appetite 4.05 (1.17–17.04) 0.0370
25(OH)D category low (<73.6nmol/l) 9.51 (2.25–57.07) 0.0051
25(OH)D category middle (73.6–110.05nmol/l) Reference category Reference category
25(OH)D category high (>110.05nmol/l) 1.31 (0.21–8.66) 0.7681
Table only shows significant variables. (AIC = 85.50)
doi:10.1371/journal.pone.0125997.t001
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However, when we performed a second analysis in which we included serum 25(OH)D con-
centrations as a categorical variable, we found that low vitamin D status was an independent
predictor of short term mortality.
The finding that there was a relationship between low serum 25(OH)D concentrations and
mortality is consistent with numerous human studies [13, 42, 43]. In addition, the observation
that there was not a linear relationship between vitamin D status and survival is also consistent
with studies in human patients [11, 40]. Several human studies have reported that there is min-
imal benefit of having high serum 25(OH)D concentrations and a number have linked high vi-
tamin D status to negative health outcomes [40, 44].
There are a wide range of potential mechanisms by which low vitamin D status may influ-
ence health outcomes. The vitamin D receptor is expressed on many immune cell types and it
is clear that vitamin D can modulate both the innate and acquired immune responses via ef-
fects on monocytes, macrophages, dendritic cells and lymphocytes [45, 46]. Vitamin D has
also been shown to profoundly modulate pro-inflammatory responses [47, 48]. The pleiotro-
pic extra-skeletal effects of vitamin D also extends to vascular function [49] and cellular prolif-
eration and differentiation [50]. Supplementation with vitamin D has also been shown to
reduce pro-inflammatory cytokines in patients with cardiovascular disease [51]. The renin-
angiotensin system is also negatively regulated by vitamin D [52, 53]. Up-regulated renin-
angiotensin activity is associated with systemic hypertension, renal dysfunction, vascular dam-
age [54] and cardiac hypertrophy [55]. Vitamin D is also inversely associated with parathyroid
hormone, although this change is not seen in all patients with hypovitaminosis D [56], and ex-
cess parathyroid hormone has been related to increased risk of heart failure [57]. All of these
diverse effects of low vitamin D concentrations may impact on survival in domesticated cats.
Our study also demonstrated that reduced appetite was an independent predictor of short
term mortality in cats. This finding is similar to human studies where reduced appetite has
been linked to poor health outcomes in elderly patients [58]. However, serum 25(OH)D con-
centrations remained a significant predictor of mortality when the results were corrected for re-
duced appetite. This suggests that the association between low serum vitamin D concentrations
and mortality is not simply due to reduced dietary intake of vitamin D in hospitalised cats.
The study also demonstrated that potassium concentrations were linked to mortality with
increasing potassium concentrations associated with poor survival outcomes. High serum po-
tassium concentrations have been associated with mortality in critical care patients, even when
increases in potassium are modest [59], and in patients with cardiac and renal disease [60]. The
mechanism(s) by which hyperkalemia influences mortality are unclear. However raised potas-
sium concentrations can result in altered neurological, cardiac and muscular function [59].
Furthermore, declining renal function is also associated with hyperkalemia [61] and hyperkale-
mia has been shown to be associated with serious infections and haemorrhage [59] which may
in part explain its association with mortality.
Table 2. Results of logistic regression model combining vitamin D as a categorical variable using 25
(OH)D as a binary predictor of lower tertile versusmiddle and upper tertiles combined.
Variable Odds ratio (95% CI) P value
Potassium 4.14 (1.34–14.21) 0.0161
Reduced appetite 4.02 (1.16–16.83) 0.0379
25(OH)D category low (<73.6nmol/l) 8.27 (2.54–31.52) 0.0008
Table only shows significant predictors. (AIC = 83.58)
doi:10.1371/journal.pone.0125997.t002
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In contrast to human medicine, little is known about the factors which are involved in all-
cause mortality in cats. Previous studies have focused particularly on cats admitted to an inten-
sive care unit (ICU), rather than across a wider hospital population [62, 63]. Therefore, the use
of vitamin D to predict survival in a general hospital population is an important feature of this
study. A previous reported predictor of feline survival is the Feline Acute Patient Physiologic
and Laboratory Evaluation (Feline APPLE) Score [63]. This scoring system has been validated
only for feline ICU patients and requires several clinical and diagnostic parameters to be as-
sessed. A univariable measure such as serum 25(OH)D concentration may provide a simpler
and more readily usable predictor of mortality.
It cannot be concluded that serum 25(OH)D is causally linked to mortality from our finding
that low vitamin D status is an independent risk factor of 30 day mortality in hospitalized, ill
cats. This would require further prospective studies, including randomized, placebo controlled
supplementation studies of cats with low vitamin D status. In light of our finding that cats with
25(OH)D concentrations in the upper tertile had a similar incidence of mortality as cats in the
middle tertile, future studies should focus on assessing whether correction of hypovitaminosis
D improves health outcomes. This approach is supported by observations from human trials in
critically ill patients [64]. Similarly, a study investigating the effects of vitamin D on cardiovas-
cular morbidity and mortality, revealed that although supplementation improved overall sur-
vival, the effects were only significant in vitamin D deficient patients [65].
In conclusion, this study supports the hypothesis that low serum vitamin D status is predic-
tive of 30 day mortality in hospitalised cats. The finding that low serum 25(OH)D concentra-
tions are negatively correlated with survival supports the initiation of follow up clinical trials to
examine the influence of vitamin D supplementation on disease outcome. Our study also indi-
cates that domesticated cats with spontaneous illnesses may provide a valuable alternative to
rodent models in which the effects of vitamin D on health outcomes can be probed without the
need to induce disease in otherwise healthy animals.
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Association of Vitamin D Status and Clinical Outcome in Dogs with
a Chronic Enteropathy
H. Titmarsh, A.G. Gow, S. Kilpatrick, J. Sinclair, T. Hill, E. Milne, A. Philbey, J. Berry, I. Handel, and
R.J. Mellanby
Background: Dogs with a chronic enteropathy (CE) have a lower vitamin D status, than do healthy dogs. Vitamin D sta-
tus has been associated with a negative clinical outcome in humans with inflammatory bowel disease.
Objectives: To examine the relationship between serum 25 hydroxyvitamin D (25(OH)D) concentrations at diagnosis and
clinical outcome in dogs with a CE.
Animals: Forty-one dogs diagnosed with CE admitted to the Royal Dick School of Veterinary Studies, Hospital for Small
Animals between 2007 and 2013.
Methods: Retrospective review. Serum 25(OH)D concentrations were compared between dogs which were alive at follow
up or had died because of non-CE-related reasons (survivors) and dogs which died or were euthanized due to their CE (non-
survivors). A binary logistic regression analysis was performed to determine significant predictors of death in dogs with CE.
Results: Serum concentrations of 25(OH)D at the time a CE was diagnosed were significantly lower in nonsurvivors
(n = 15) (median nonsurvivors 4.36 ng/mL, interquartile range 1.6–17.0 ng/mL), median survivors (n = 26) (24.9 ng/mL
interquartile range 15.63–39.45 ng/mL, P < .001). Serum 25(OH)D concentration was a significant predictor of death in dogs
with CE (odds ratio 1.08 [95% CI 1.02–1.18)]).
Conclusions: Serum 25(OH)D concentrations at diagnosis are predictive of outcome in dogs with CE. The role of vitamin
D in the initiation and outcome of chronic enteropathies in dogs is deserving of further study.
Key words: 25 (OH)D; Prognostic; Inflammatory bowel disease.
Chronic enteropathies in dogs are a major cause ofmorbidity and mortality.1 A diagnosis of chronic
enteropathy (CE) is made in dogs which have a several
week history of gastrointestinal signs such as weight
loss, vomiting, and diarrhea, and the absence of an
underlying etiology based on diagnostic evaluation and
the presence of an inflammatory infiltrate within gas-
trointestinal biopsies.2 The pathogenesis of CE in dogs
is considered to be multifactorial and includes factors
such as abnormal mucosal immunity, disrupted epithe-
lial barrier function, altered intestinal microbial flora,
environment, and genetics.2,3
Dogs with CE have lower serum concentrations of 25
hydroxyvitamin D (25(OH)D), which is the vitamin D
metabolite widely used to assess vitamin D status, than
do healthy dogs and hospitalized dogs with nongas-
trointestinal illnesses.4,5 In addition, the severity of the
clinical signs, as assessed by the canine inflammatory
bowel activity index (CIBDAI), correlates with serum
25(OH)D concentrations in dogs with a CE.5 However,
the prognostic significance of serum 25(OH)D concen-
trations has not been investigated in dogs with a CE.
In contrast, the relationship between vitamin D status
and IBD has been extensively explored in human medi-
cine. In human patients with IBD, notably ulcerative
colitis and Crohn’s disease, vitamin D deficiency is a
frequent finding.6–9 Higher predicted vitamin D status
has been associated with a reduced risk of developing
Crohn’s disease.10 Among people with IBD, 25(OH)D
concentrations are related to disease severity scores and
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patient quality of life.11–13 Low plasma 25(OH)D con-
centrations have also been associated with an increased
risk of surgery and longer hospitalization periods in
patients with either Crohn’s disease or ulcerative colitis.14
In addition, normalization of 25(OH)D concentrations in
patients with Crohn’s disease has been associated with a
reduction in the risks associated with surgery.14 Vitamin
D status has also been linked to IBD treatment out-
comes, as low pretreatment vitamin D status has been
associated with reduced durability of response to antitu-
mor necrosis factor (TNF)-a treatment.15 Studies have
also demonstrated improvements in disease activity
scores and quality of life scores in Crohn’s disease
patients supplemented with oral vitamin D.16,17
The hypothesis of this study was that the vitamin D
status would not be different in dogs that died or were
euthanized because of the complications associated with
their CE compared to dogs which were alive at follow
up or had died because of diseases unrelated to their
CE. The aim of this study was to measure serum con-
centrations of 25(OH)D, alongside a range of clinical
and biochemical variables, in dogs with a confirmed
diagnosis of CE and known clinical outcome.
Material and Methods
Study Population
The records of dogs referred to the Hospital for Small Animals,
Royal Dick School of Veterinary Studies for investigation of
chronic gastrointestinal disease (more than 3 weeks in duration)
between 2007 and 2013 were retrospectively reviewed. Dogs were
considered eligible for inclusion in the study if they had presenting
clinical signs consistent with a CE, which included any of the fol-
lowing: vomiting, diarrhea, increased borborygmi, abdominal pain,
increased or decreased appetite, and weight loss. All dogs were
considered eligible if they had histopathological evidence of
inflammation within the small or large intestine and there were no
clinically relevant abnormalities detected on hematology, biochem-
istry, or abdominal ultrasonography, which were not attributable
to CE. In addition, a stored frozen serum sample from each dog,
collected at the time of diagnosis was required for retrospective
analysis of 25(OH)D concentrations. Hematology variables (total
white blood cell count, mature neutrophils, band neutrophils lym-
phocytes, monocytes, eosinophils, basophils, total red blood cell
counts, packed cell volume, hemoglobin, mean cell volume, mean
cell hemoglobin concentration, and platelet number) were mea-
sured on ADVIA(r) 2120i System with Autoslide.a Biochemistry
variables (albumin, alanine transaminase [ALT], alkaline phos-
phatase [ALP], bile acids, bilirubin, total calcium, creatinine, glob-
ulin, phosphate, potassium, sodium, chloride, urea, and glucose)
were measured on an ILab650 biochemistry analyzer.b Clinical
records were also reviewed for the results of fecal parasitology.
Canine inflammatory bowel disease activity index (CIBDAI) scores
were calculated as follows: appetite, activity levels, vomiting, fecal
consistency, fecal frequency, and weight loss were each scored
from 0 to 3. A score of 0 indicated no changes were present, a
score of one indicated mild changes, 2 moderate changes, and 3
severe changes. In addition, a score of one point was added if the
feces contained blood or mucus. The area of intestinal tract which
was biopsied (duodenum or duodenum and colon) was determined
based on the presenting clinical signs and was at the discretion of
the primary clinician managing the case. A diagnosis of CE was
made if there was histological evidence of intestinal inflammation
and no clear underlying cause.
Vitamin D Analysis
Serum samples retained for 25(OH)D measurement were fro-
zen after being used for routine biochemical analysis. They were
stored at 70°C before being sent to the laboratory for analysis
on dry ice. Serum 25(OH)D has been shown to be stable under
these conditions.18 Serum concentrations of 25(OH)D were mea-
sured as previously described in detail.19,20 Samples were
extracted using acetonitrile and applied to C18 Silica Sep-paks.
Separation of metabolites was by straight phase high perfor-
mance liquid chromatography (HPLC)c using a Hewlett-Packard
Zorbax-Sil Columnd eluted with hexane:propan-2-ol:methanol
(92 : 4 : 4). Serum 25(OH)D2 and 25(OH)D3 were measured
separately by application to a second Zorbax-Sil Column eluted
with hexane:propan-2-ol (98 : 2) and quantified by ultraviolet
absorbance at 265 nm and corrected for recovery (sensitivity
5 nmol/l, intra- and interassay coefficients of variation 3.0 and
4.2%, respectively).21 Total 25(OH)D was defined as the sum of
25(OH)D2 and 25(OH)D3. This laboratory is accredited by
CPA UK (CPA number 0865) and has been certified as proficient
by the international Vitamin D Quality Assurance Scheme
(DEQAS).
Histopathology
Where available, the slides of the original duodenal biopsies
were reviewed by a single veterinary pathologist. A qualitative
scoring system (World Small Animal Veterinary Association
[WSAVA] Standards for the Diagnosis of Gastrointestinal Inflam-
mation in Endoscopic Biopsy Samples)22 was used to assess the
degree of inflammation. The template for this system assesses the
following histological changes (villous stunting, epithelial injury,
crypt distension, lacteal dilatation, and mucosal fibrosis) and
inflammatory infiltrates (intraepithelial lymphocytes, lamina pro-
pria lymphocytes and plasma cells, lamina propria eosinophils,
and lamina propria neutrophils). The changes for each of the vari-
ables listed were graded as normal (0), mild (1), moderate (2), or
severe (3). The sums of all these variables were added together to
determine an intestine inflammatory score which ranged from 0
(normal) to 30 (very severe).
Outcome
For each dog enrolled, follow-up data was obtained by review-
ing clinical records and by telephone contact with referring
veterinary surgeons and owners. Outcome was recorded as sur-
vivors if the dogs were alive at follow up or had died because of
a non-CE-related illnesses or nonsurvivors if dogs had died or
were euthanized because of the complications associated with
CE.
Statistical Analysis
Univariable measures were compared between dogs which sur-
vived and nonsurviving dogs using a Mann–Whitney U-test. A
Fisher’s exact test was used to compare the sex of surviving and
nonsurviving dogs. A binary logistic regression model was used to
estimate the association between outcome (survivors versus non-
survivors) and serum 25(OH)D concentrations conditional on a
range of other candidate predictors. Stepwise selection of variables
was used to minimize Akaike Information Criteria (AIC), which is
a parameter-penalized measure of model fit. Duodenal histology
scores were classified into 3 approximate tertiles (low <7, medium
7–8, high >8) for the regression model. The statistical analysis was
performed using R statistical system (R Development Core Team
2012).
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Ethical Review
Informed consent for the use of residual clinical blood samples
for research purposes was obtained at admission for each dog
enrolled. Ethical approval for the study was obtained from the
University of Edinburgh’s Veterinary Ethical Review Committee.
Results
Signalment
Forty-one dogs were included in the study. There
were 15 nonsurvivors and 26 survivors. In the nonsur-
vivors group, 2 dogs were intact males, 7 were neutered
males, 1 was an intact female, and 5 were neutered
females. In the survivors group, 7 dogs were intact
males, 11 were neutered males, and 8 were neutered
females. Breeds in the nonsurvivors groups included
Border Collie (n = 1), Boxer (n = 3), Cavalier King
Charles Spaniel (n = 1), Cross Breed (n = 3), German
Short Haired Pointer (n = 1), Hungarian Vizsla (n = 1),
Italian Greyhound (n = 1), Pyrenees Mountain Dog
(n = 1), Springer Spaniel (n = 1), Staffordshire Bull Ter-
rier (n = 1), and West Highland White Terrier (n = 1).
In the survivors group, breeds included Border Terrier
(n = 1), Boxer (n = 7), Cocker Spaniel (n = 1), Cavalier
King Charles Spaniel (n = 1), Chinese Crested (n = 1),
Cross Breed (n = 1), Irish Setter (n = 2), Labrador
Retriever (n = 2), Lurcher (n = 2), Rottweiler (n = 1),
Shar-pei (n = 1), Shetland Sheep Dog (n = 1), Springer
Spaniel (n = 1), Staffordshire Bull Terrier (n = 1), Toy
Poodle (n = 2), and Yorkshire Terrier (n = 1).
Clinical Findings
The median duration of clinical signs at diagnosis
was 3 months in the nonsurvivors (range 1–10 months)
and 3.5 months (range 0.75–24 months) in the survivors
group. Hematology, biochemistry, and abdominal ultra-
sonography findings did not reveal any clinically rele-
vant abnormalities in any of the 41 dogs which could
not be attributed to their CE. Fecal parasitology was
performed in 36 dogs and did not reveal evidence of
parasitic infection in any of the samples. Twelve dogs
underwent gastroduodenoscopy and 29 dogs had both
gastroduodenoscopy and colonoscopy.
Histopathological examination of duodenal biopsies
in the nonsurvivors revealed lymphoplasmacytic enteri-
tis (5) and mixed lymphoplasmacytic and eosinophilic
enteritis (10). In the survivor group histopathological
diagnosis based on duodenal biopsies included lympho-
plasmacytic enteritis (8) and mixed lymphoplasmacytic
and eosinophilic enteritis (18). Follow up for the sur-
vivor group ranged from 18 to 75 months (median
27 months). In the nonsurvivors group the follow up
ranged from 4 days to 24 months (median 2 months).
Outcome
Fifteen dogs died or were euthanized as a result of
CE (Tables 1 and 2). The age of the dogs at presenta-
tion which subsequently died or were euthanized
because of their CE ranged from 9 to 114 months
(median 96 months). Dogs which subsequently died had
been treated with dietary changes and antibiotics
(n = 2), dietary changes, prednisolone and antibiotics
(n = 7), and dietary changes, antibiotics, prednisolone
and other immunosuppressive medications (n = 6).
Twenty-six dogs did not die as a result of gastrointesti-
nal disease (Tables 1 and 2). Sixteen were alive at fol-
low up and 10 had died because of nongastrointestinal
diseases. The age of the dogs in the survivors group
ranged from 6 to 96 months (median 60.5 months).
Dogs in this group were treated with dietary changes
and antibiotics (n = 10), dietary changes and pred-
nisolone (n = 1), dietary changes, prednisolone and
antibiotics (n = 3) and dietary changes, prednisolone,
antibiotics and other immunosuppressive drugs (n = 1),
diet alone (n = 10), and gastroprotectants (n = 1).
Univariable analysis revealed that serum 25(OH)D,
albumin and total calcium concentrations were signifi-
cantly lower in nonsurvivors compared to survivors
(Table 1, Fig 1). Age and CIBDAI scores were signifi-
cantly higher in nonsurvivors compared to survivors
(Table 1). There was no significant difference in the
number of male and female dogs between the 2 groups
(Table 1).
A binary logistic regression model was performed to
estimate the association between outcome and serum 25
(OH)D concentrations conditional on a range of other
candidate predictors. Canine inflammatory bowel dis-
ease activity index was not included in this model as it
has previously been shown that this measure strongly
Table 1. Univariable analysis of clinical and biochemi-
cal variables in surviving and nonsurviving dogs. The





(n = 15) P Value
Age (months) 60.5 (36–73) 96.0 (60–108) .004
Calcium mg/dL 9.68 (9.04–10.12) 8.24 (6.76–9.04) .002
Calcium mmol/L 2.42 (2.26–2.53) 2.06 (1.69–2.26)
Albumin mg/dL 3.34 (2.73–3.52) 2.45 (1.3–2.69) .0007
Albumin g/L 33.35 (27.3–35.2) 24.50 (13–26.9)
CIBDAI 6 (5–9) 10 (7–12) .0022
25(OH)D ng/mL 24.90 (15.63–39.45) 4.3 (1.6–17.0) .0003
Male/female 18/8 9/6 .73
Table 2. Impact on model akaike information criteria
(AIC) after addition of dropped predictors. An increase
in AIC represents a poorer parameter-penalized model
fit.
Added Predictor AIC
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correlates with serum 25(OH)D concentrations.5 In this
analysis duodenal histology severity scores were also
included which were available for 34 of the 41 dogs.
There was no significant difference in the histopathol-
ogy scores between dogs which died compared to the
ones which survived (P = .06). There were 10 dogs with
a score of <7, 10 dogs with a score of 7 or 8, and 14
dogs with a score of 9 or greater. The initial model
included age, sex, histopathology score as a tertile,
serum calcium, albumin, and 25(OH)D concentrations.
After stepwise AIC selection, the optimal predictive
final model used serum 25(OH)D concentrations and
age demonstrating that vitamin D status was an inde-
pendent predictor of mortality in dogs with CE. The
odds ratio for death was 1.08 (95% confidence interval
1.02–1.18) for vitamin D status and for age was 0.97
(95% confidence 0.93–1.00). Table 2 shows the conse-
quences on model fit following the reintroduction of
discarded predictors, demonstrating that the model
based on 25(OH)D concentrations and age was optimal.
Discussion
The main finding of this study is that serum 25(OH)
D concentrations are significantly lower at the time of
diagnosis in dogs which died or were euthanized as a
result of a CE. This is an important finding as it is pre-
sently difficult to predict outcomes in dogs with a CE.
Older age, hypoalbuminemia, and higher CIBDAI
scores are predictive of a poorer outcome in dogs with
a CE, findings which are further supported by our
research.1,23,24 This study, which demonstrates that 25
(OH)D concentration at point of diagnosis is a prog-
nostic marker in dogs with a CE, will provide addi-
tional prognostic information to owners and
veterinarians managing dogs with a CE. Further work
is needed to determine the optimal cut-off value for
vitamin D as a prognostic marker.
The mechanism(s) underlying a hypovitaminosis D
state in canine CE is unknown. Reduced dietary intake
of vitamin D in dogs with a CE maybe an important
cause of hypovitaminosis D especially as dogs do not
cutaneously produce vitamin D.25 As low vitamin D sta-
tus in dogs with a CE has been associated with a
decreased appetite5, this may, in part, explain the
reduced serum 25(OH)D concentrations that are fre-
quently observed in dogs with a CE. However, dogs with
a CE were found to have a lower 25(OH)D concentra-
tions than hospitalized ill dogs with nongastrointestinal
illnesses, many of which also have reduced appetites.5
Consequently, the influence of appetite on the vitamin D
status in dogs with a CE remains unclear.
Circulating 25(OH)D is bound to vitamin D binding
protein and albumin.26 Enteric loss of albumin is
regarded to be a significant problem in many dogs with
a CE, notably in cases of protein losing enteropathies.27
Consequently, loss of protein-bound vitamin D into the
gastrointestinal tract could account for the low vitamin
D status in some dogs with a CE. This may explain our
earlier finding of a correlation between serum albumin
concentration and vitamin D status in dogs with a CE.5
Similarly, albumin concentrations has also been shown
to be a predictor of serum 25(OH)D concentration in
humans with IBD.28 Malabsorption might also con-
tribute to low vitamin D status in human patients with
Crohn’s disease and this could potentially influence
serum 25(OH)D concentrations in dogs with CE. How-
ever, while vitamin D absorption appears to be reduced
in patients with Crohn’s disease compared to healthy
controls, there seems to be substantial variation in
absorption of vitamin D in these patients.29 Further
studies are needed in both people and dogs with CE to
clarify the potential role of vitamin D malabsorption in
driving a hypovitaminosis D state.
Although hypovitaminosis D in CE has traditionally
been considered to be a result of intestinal disease, there
is growing evidence that hypovitaminosis D may con-
tribute to the initiation of intestinal inflammation. Sup-
porting evidence for a link between hypovitaminosis D
and CE comes from rodent models which have demon-
strated that vitamin D receptor knock out (VDR/)
mice are more susceptible to experimental forms of
inflammatory bowel disease. For example, experimen-
tally induced colitis in VDR/ mice was significantly
more severe compared to wild-type mice.30,31 Further-
more it has also been demonstrated that supplementing
wild-type mice with vitamin D can decrease the severity
of gastrointestinal inflammation with chemical induced
colitis.30 In addition, it has been shown that feeding
mice a vitamin D-restricted diet can predispose to
IBD.32 A recent meta-analysis of animal and human tri-
als concluded that while many studies reported an
improvement with supplementing vitamin D, there is
insufficient evidence to currently recommend vitamin D
treatment for human cases of IBD.33 Therefore, further
research is needed into the potential role of vitamin D
in the management of these diseases.
The vitamin D receptor is expressed on many
immune cell types and it is clear that vitamin D can
modulate both the innate and acquired immune
responses via effects on monocytes, macrophages, den-
dritic cells, and lymphocytes.34,35 Vitamin D has also
been shown to profoundly modulate proinflammatory
responses.36,37 Therefore, lack of vitamin D might drive
abnormal inflammatory and immune processes.
Fig 1. Serum 25 hydroxyvitamin D concentrations in surviving
and nonsurviving dogs with a chronic enteropathy.
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Loss of tolerance to normally harmless bacterial and
dietary antigens is hypothesized to be important for the
development of canine CE.3 Vitamin D may also be
important in regulating the immune response to com-
mensal gut flora and maintaining normal bacterial pop-
ulations. For example, dysbiosis was also reported in
VDR/ mice and Cyp27B1/ mice38 and dysbiosis
may contribute to CE in dogs.39
There is growing evidence linking vitamin D defi-
ciency with disrupted intestinal mucosal barrier func-
tion. It has been proposed that altered epithelial barrier
function, resulting in increased epithelial permeability,
leads to increased exposure of the mucosal immune sys-
tem to luminal antigens and that this may contribute to
the initiation and perpetuation of chronic inflamma-
tion.40 This hypothesis is supported by the observation
that intestinal permeability is increased in people with
naturally occurring inflammatory bowel disease and
their unaffected relatives.41 Similar findings have been
reported in dogs with naturally occurring CE where
increased paracellular permeability has been demon-
strated by lactulose to rhamnose absorption tests.42,43
In vitro active vitamin D metabolite, 1,25-dihydroxyvi-
tamin D3 [1,25(OH)2D3], markedly enhances tight junc-
tions by increasing tight junction protein expression.44
The same study also demonstrated that VDR/ mice
were more susceptible to mucosal injury than wild-type
mice. These results suggest that vitamin D might be
important in mucosal integrity and gastrointestinal bar-
rier function which could contribute to CE.
Limitations of this study include the lack of standard-
ization in treatment regime, which is a result of the ret-
rospective nature of the study design.
In summary, this study demonstrates the serum vita-
min D concentrations are predictive of clinical outcome
in dogs with CE. Although, causality cannot be inferred
from these results, the finding that low serum 25(OH)D
concentrations are negatively correlated with outcome
highlights the need to further examine the relationship
between vitamin D homeostasis and disease develop-
ment and outcome in dogs with CE.
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Vitamin D deficiency, as assessed by serum concentrations of 25 hydroxyvitamin D (25
(OH)D), has been linked to the development of over-zealous and inappropriate inflamma-
tion in humans. However, the relationship between vitamin D status and inflammation in
dogs is ill-defined. Chronic enteropathies (CE) are frequently diagnosed in client owned
dogs, have a wide range of serum 25(OH)D concentrations, and represent a spontaneous
model in which to probe the relationship between vitamin D and inflammation. The hypothe-
sis of this study was that vitamin D status would be negatively associated with systemic and
gastrointestinal inflammation in dogs with a CE. The aim of this study was to examine the
relationship between serum 25(OH)D concentrations and markers of systemic and gastroin-
testinal inflammation in a cohort of dogs with CE.
Methods and Materials
Serum 25(OH)D concentrations, together with neutrophil, monocyte, eosinophil and lym-
phocyte counts, duodenal histopathology scores, serum IL-2, IL-6, IL-8 and TNFα concen-
trations and were measured in 39 dogs with histologically confirmed CE. A linear regression
model examined the relationship between serum 25(OH)D status and measures of
inflammation.
Results
Serum 25(OH)D concentrations were negatively associated with neutrophil and monocyte
counts, duodenal histopathology scores and serum IL-2 and IL-8 concentrations. Dogs with
low serum 25(OH)D concentrations typically had an inflammatory signature characterised
by high monocyte and neutrophil numbers together with low lymphocyte numbers. There is
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a need to establish whether low vitamin D status is a cause or consequence of
inflammation.
Introduction
The traditional functions of vitamin D relate to its role in the maintenance of calcium homeo-
stasis and bone metabolism. In recent decades, many cell types have been shown to express the
vitamin D receptor, and the physiological roles of vitamin D have been shown to extend
beyond skeletal metabolism [1, 2]. Consequently, numerous studies have examined the rela-
tionship between the immune response and vitamin D status as assessed by serum 25 hydroxy-
vitamin D (25(OH)D) concentrations in human patients. There is a growing body of evidence
that vitamin D status is negatively associated with markers of inflammation, including circulat-
ing pro-inflammatory cytokines and acute phase proteins in a number of diseases including
obesity [3, 4], inflammatory polyarthritis [5], diabetes mellitus [6], autoimmune diseases [7],
inflammatory bowel disease [8, 9], and human immunodeficiency virus [10]. Furthermore, low
vitamin D status has been associated with increased markers of inflammation in healthy
humans [11–13].
The reasons why vitamin D status is negatively associated with inflammation is unclear.
The vitamin D receptor (VDR) is found on most immune cells including macrophages, den-
dritic cells, T-lymphocytes and B-lymphocytes [14]. Vitamin D can promote immune tolerance
by increasing T-regulatory cell populations [15], inhibiting the production of pro-inflamma-
tory cytokines and increasing the production of anti-inflammatory cytokines [16–22].Vitamin
D is also known to enhance the innate immune response to bacteria, by increasing the produc-
tion of anti-microbial peptides such as cathelicidin [18, 23].
The relationship between vitamin D status and inflammation is poorly understood in dogs.
Serum 25(OH)D concentrations are commonly reduced in a number of inflammatory diseases
in dogs including congestive heart failure [24], Spirocerca lupi infections [25], protein losing
enteropathy [26, 27] and renal disease [28]. Low vitamin D status has been negatively associ-
ated with C-reactive protein (CRP) in dogs with haemoabdomen [29]. However, other studies
have reported a positive association between vitamin D and CRP concentrations in racing sled
dogs [30]. Consequently, further work is needed to clarify the relationship between vitamin D
and inflammation in dogs.
Dogs with chronic enteropathies (CE) represent a spontaneous model in which to explore
the relationship between vitamin D status and inflammation. We have previously demon-
strated the dogs with CE can have a range of vitamin D concentrations, ranging from profound
deficiency to sufficiency [26, 31]. However, the relationship between 25(OH)D concentrations
and inflammation in dogs with CE is poorly understood. A number of markers of systemic
inflammation, including serum cytokines and leukocyte profiles can be measured in dogs [32].
In addition, the WSAVA gastrointestinal histopathology scoring system for endoscopic biop-
sies [33] provides a standardized means of assessing the extent of inflammation within gastro-
intestinal biopsies from dogs with a CE.
The hypothesis of this study was that vitamin D status would be negatively associated with
local and systemic markers of inflammation in dogs with a CE. The objectives were to investi-
gate the relationship between serum concentrations of 25(OH)D and blood neutrophil, lym-
phocyte, monocyte and eosinophil numbers, duodenal histopathology inflammation scores,
and serum cytokine concentrations in dogs with histologically confirmed CE.
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Material and Methods
The records of dogs referred to the Hospital for Small Animals, Royal (Dick) School of Veteri-
nary Studies for investigation of chronic gastrointestinal disease of more than three weeks in
duration were retrospectively reviewed. Inclusion criteria including the following clinical signs,
common reported in dogs with CE: vomiting, diarrhoea, increased borborygmi, abdominal
pain, increased or decreased appetite and weight loss and also that the dogs had histopatholog-
ical evidence of inflammation within the small or large intestine. Furthermore, there were no
clinically significant abnormalities detected on hematology, biochemistry or abdominal ultra-
sonography indicative of non-gastrointestinal diseases for any of the dogs enrolled. In addition,
the faeces of all dogs were negative for both helminth and Giardia infections.
Haematology variables, which included total white blood cell count, mature neutrophils,
band neutrophils, lymphocytes, monocytes, eosinophils, basophils, total red blood cell counts,
packed cell volume, haemoglobin, mean cell volume, mean cell haemoglobin concentration
and platelet number were measured on ADVIA(r) 2120i System with Autoslide (Siemens Med-
ical Solutions Diagnostics Ltd California, USA). At least a 100-white blood cell manual differ-
ential count was undertaken to establish the concentrations of neutrophils, monocytes,
lymphocytes, eosinophils and basophils. Blood smears were evaluated under the direct supervi-
sion of a Board-certified veterinary clinical pathologist in every case. Biochemistry variables
were measured on an ILab650 biochemistry analyser, (Diamond Diagnostics, USA). The area
of intestinal tract which was biopsied (duodenum or duodenum and colon) was at the discre-
tion of the primary clinician managing the case and based on presenting clinical signs. A diag-
nosis of CE was made if there was histological evidence of intestinal inflammation and no
underlying aetiology was identified by on abdominal ultrasound, faecal samples or blood tests.
Serum samples retained for 25(OH)D measurement were frozen after being used for routine
biochemical analysis. They were stored at –70°C before being sent to the laboratory for analysis
on dry ice. Serum concentrations of 25(OH)D were measured as previously described in detail
[34, 35]. Samples were extracted using acetonitrile and applied to C18 Silica Sep-paks. Separa-
tion of metabolites was by straight phase high performance liquid chromatography (HPLC)
(Waters Associates, Milford, MA, USA) using a Hewlett-Packard Zorbax-Sil Column
(Hichrom, Reading, UK) eluted with hexane:propan-2-ol:methanol (92:4:4). Serum 25(OH)D2
and 25(OH)D3 were measured separately by application to a second Zorbax-Sil Column eluted
with hexane:propan-2-ol (98:2) and quantified by ultraviolet absorbance at 265 nm and cor-
rected for recovery (sensitivity 5 nmol/L, intra- and inter-assay coefficients of variation 30%
and 42%, respectively) [36]. This Supraregional Assay Service laboratory is accredited by CPA
UK (CPA number 0865) and has been certified as proficient by the international Vitamin D
Quality Assurance Scheme (DEQAS). Total 25(OH)D was defined as the sum of 25(OH)D2
and 25(OH)D3.
Canine pro-inflammatory cytokines (IL-2, IL-6, IL-8 and TNF-α) were measured from
serum samples using a multiplex electrochemiluminescence immunoassay system (Meso Scale
Discovery; MSD) as previously described[32]. Assay diluent (25 μL) was added to all wells,
plates sealed and incubated for 30 min at room temperature on an orbital shaker (600 rpm).
Samples and standards, diluted in assay diluent, were added at 25 μL per well. Plates were again
sealed and incubated for a further 2 hours at room temperature with shaking. At the end of the
incubation period, wells were washed three times with 200 μL phosphate-buffered saline (PBS),
supplemented with 0.05% Tween 20 (Sigma–Aldrich) for 30 s, then discarded. Detection anti-
body was added at 25 μL per well, plates sealed and incubated for a further 1 h at room temper-
ature with shaking. Plates were washed three times and 150 μL of MSD Read Buffer added to
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each well, then electrochemiluminescence measured using the MSD Sector Imager 2400 plate
reader.
A single veterinary pathologist (AP) reviewed the histopathological samples. The degree of
inflammation present was assessed using a qualitative scoring system (WSAVA Standards for
the Diagnosis of Gastrointestinal Inflammation in Endoscopic Biopsy Samples) [33]. Parame-
ters which are assessed using this system include the following: histological changes (villous
stunting, epithelial injury, crypt distension, lacteal dilatation, and mucosal fibrosis) and inflam-
matory infiltrates (intra-epithelial lymphocytes, lamina propria lymphocytes and plasma cells,
lamina propria eosinophils, and lamina propria neutrophils). Changes were graded as normal
(0), mild (1), moderate (2) or severe (3). The sums of all these parameters were added together
to determine an intestine inflammatory score which ranged from 0 (normal) to 30 (very
severe).
In order to investigate the relationship between multiple inflammatory markers and serum
25(OH)D concentrations, individual variables were examined using histograms and parame-
ters which were not normally distributed (Anderson-Darling test) were transformed. Log10
transformation was undertaken except for square root transformation of eosinophil numbers
since some eosinophil numbers were zero. The relationship between age, sex and 25(OH)D
was examined using scatter plots and linear regression model. The relationship between 25
(OH)D and inflammatory parameters was investigated using linear regression models. Age
and sex was included in initial models in order to examine for any confounding effects. Final
models were selected by removing potential confounders if their removal did not worsen
model fit as assessed by the Akaike information criterion (AIC, a penalty parameter penalised
measure of model fit). As the study wanted to examine whether 25(OH)D concentrations cor-
related to an inflammatory signature, medoid based partitioning was used to assign haematol-
ogy parameters to three clusters. Three clusters was chosen on the basis of a consensus of
results from 30 cluster count algorithms [37]. These clusters were identified independently of
25(OH)D concentrations. A Kruskal Wallis test was used to determine if there was difference
in 25(OH)D concentrations between the three clusters [38]. Tukey and Kramer posthoc test
for pairwise comparisons were then used to identify which clusters differ. Data was collected
using Excel and analysed using R statistical software system [39]. A p value of<0.05 was used
to define statistical significance.
The University of Edinburgh’s Veterinary Ethical Review Committee approved the study.
Informed consent for the storage and subsequent use of residual clinical blood samples for
research purposes was obtained at admission for each dog enrolled.
Results
Thirty-nine dogs with a diagnosis of chronic enteropathies were enrolled. Breeds enrolled
included; Boxer (9), cross breed (5), Labrador (2), Lurcher (2), Springer Spaniel (2), Cavalier
King Charles Spaniel (2), Staffordshire Bull Terrier (2), and one of each of the following breeds;
Irish Setter, Italian Greyhound, Toy Poodle, Shar-pei, Yorkshire Terrier, Pyrenees Mountain
Dog, Hungarian Vizsla, Greyhound, German Short Haired Pointer, West Highland White Ter-
rier, Cocker Spaniel, Dogue de Bordeaux, Shetland Sheep dog, Border Collie and a Border Ter-
rier. The age range of dogs included was 6 to 136 months (median 65 months). Haematology,
biochemistry, faecal parasitology and abdominal ultrasonography did not reveal any significant
clinical abnormalities in any of the 39 dogs. Sixteen dogs underwent upper gastrointestinal
endoscopy and 23 dogs had both upper and lower gastrointestinal endoscopy. Thirty- two dogs
had duodenal biopsy samples which were available for histological review by a veterinary
pathologist who was blinded to the clinical history and vitamin D status of the dogs. Only 32
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samples were available for review as the remainder could not be retrieved from archived stores.
Cytokine analysis was available in 23 cases as archived serum samples were not available for all
cases.
Age and sex were not predictive of serum 25(OH)D concentrations in a linear regression
model. The relationships between serum 25(OH)D concentrations and haematology, duodenal
inflammation score and serum cytokine results are shown in Fig 1. Neutrophil and monocyte
counts, duodenal histopathology score and serum IL-2 and IL-8 concentrations were negatively
associated with 25(OH)D concentrations (Table 1). Three clusters were identified in the hae-
matology data (Figs 2 and 3). There was a significant difference in 25(OH)D concentrations
between the three clusters (p = 0.009). Post-test analysis revealed a significant difference
between clusters 2 and 3 (p = 0.006).
Fig 1. Relationship between haematology, serum cytokines and duodenal inflammatory score and serum 25(OH)D concentrations.
doi:10.1371/journal.pone.0137377.g001
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Discussion
The central finding of this study is that serum 25(OH)D concentrations negatively correlate
with systemic markers of inflammation including neutrophil and monocyte counts, serum IL-2
and IL-8 concentrations and local inflammation as measured by duodenal histopathology
scores. Linear regression and medoid based partitioning analysis demonstrated that dogs with
low vitamin D status had an inflammatory signature consisting of high neutrophil and mono-
cyte counts and low lymphocyte numbers. A typical stress and/or inflammatory leukogram in
dogs consist of neutrophilia, monocytosis and lymphopenia. These changes provide evidence
of an association between reduced serum 25(OH)D concentrations and systemic inflammation
in this population of dogs.
The results of this study also show that IL-2 and IL-8 concentrations are increased in the
serum of dogs with CE and associated with lower 25(OH)D concentrations. Interleukin-2 acts
on activated lymphocytes resulting in their expansion, and differentiation into cytotoxic lym-
phocytes, natural killer cells and T helper cells [40]. Interleukin-2 is under direct transcrip-
tional regulation by 1,25(OH)2D and can decrease IL-2 production [41]. Culture of T
lymphocytes with vitamin D from patients with systemic lupus erythematous decreased pro-
duction of IL-2 [42]. Similarly, vitamin D supplementation has been associated with decrease
in circulating IL-2 concentrations in children with atopy [43]. In addition, increased IL-2
concentrations have been reported in vitamin D insufficient adults [44]. Serum IL-8 concentra-
tions were also increased in this population of dogs with CE and lower 25(OH)D concentra-
tions. In human IBD, IL-8 is an important inflammatory mediator, playing a role in the
initiation and maintenance of IBD by recruiting neutrophils into the inflamed gastrointestinal
tract [45]. An increase in serum IL-8 concentrations have also been reported in human patients
with IBD [46]. Vitamin D has been shown to exert anti-inflammatory effects by decreasing
IL-8 production in intestinal cell cultures [47]. Our results also indicate that low serum vitamin
D concentrations are associated with more severe inflammation as assessed by duodenal histo-
pathology scores. This provides evidence of an association between intestinal inflammation
and reduced vitamin D concentrations.
It is unclear if the low 25(OH)D concentrations observed in inflammatory diseases are caus-
ally related to inflammation or if lower vitamin D status occur as a consequence of the inflam-
matory process itself. Serum 25(OH)D concentrations have been shown to decrease following
elective surgical procedures in human patients, coupled with increases in inflammatory mark-
ers such as CRP, suggesting vitamin D is a negative acute phase reactant [48]. Serum 25(OH)D
Table 1. Results of logistic regression model of inflammatory parameters on serum 25(OH)D
concentrations.
Variable Co-efficient (SE) P value
Neutrophil number (log10) -0.011 (0.003) <0.001 *
Monocyte number (log10) -0.016 (0.004) <0.001 *
Eosinophil number (sqrt) 0.008 (0.004) 0.09
Lymphocyte number (log10) 0.005 (0.004) 0.16
Duodenal histopathology score (log10) -0.012 (0.004) 0.006 *
IL-2 (log10) -0.015 (0.007) 0.048 *
IL-6 (log10) -0.011 (0.006) 0.09
IL-8 (log10) -0.018 (0.006) 0.01 *
TNF-α (log10) -0.014 (0.007) 0.06
*denotes statistical significance P<0.05
doi:10.1371/journal.pone.0137377.t001
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concentrations also fall rapidly in other inflammatory conditions such as acute pancreatitis
[49]. Increases in pro-inflammatory cytokines have been proposed to be the cause of decreases
in serum 25(OH)D in acute inflammation. For example, changes in serum 25(OH)D over sev-
eral weeks corresponded with increases in serum pro-inflammatory cytokines, including TNF-
α, IFN-γ, IL-1β, GM-CSF and IL-6 concentrations, in patients undergoing knee arthroplasty
[50]. However, not all studies looking at illness events associated with acute inflammation have
demonstrated decreases in serum 25(OH)D concentrations [51, 52]. In addition, changes in
vitamin D status following inflammation may relate to changes in vitamin D binding proteins.
For example, serum vitamin D binding protein decreases in the face of acute inflammation
[53].
Numerous studies have investigated the potential benefit of vitamin D supplementation in a
range of inflammatory diseases. In ill patients, vitamin D administration reduces some markers
of inflammation in early chronic kidney disease [54], end-stage renal disease [55], congestive
Fig 2. Box and whisker plot of serum 25(OH)D concentrations by cluster. The box extends from 25% to 75% percentile with the median and the
whiskers extend to limits of the data.
doi:10.1371/journal.pone.0137377.g002
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heart failure [56], systemic lupus [57] and colorectal adenoma [58]. In addition markers of
inflammation decreased in elderly women with vitamin D insufficiency in response to supple-
mentation with a mega-dose of vitamin D3 [59]. However, other studies investigating the
effects of vitamin D supplementation on markers of inflammation have failed to demonstrate
in–vivo anti-inflammatory effects. For example, high dose vitamin D treatment did not result
in a decrease in inflammatory markers in people with low vitamin D status diagnosed with:
pre-diabetes and type 1 diabetes [6, 60], hypertension [61] and urticaria [62]. Furthermore,
increases in pro-inflammatory cytokines were documented in patients with osteoporosis after
vitamin D supplements were administered [63]. There are many potential explanations for
why the results of different studies reported differing effects of vitamin D supplementation on
markers of inflammation. These include differences in the duration for which vitamin D sup-
plementation was given, the type of vitamin D used for supplementation and the effects of
various diseases. In one meta-analysis it appears that the benefits of vitamin D in reducing
inflammatory markers is dependent on the disease state studied and initial, pre-treatment 25
(OH)D concentrations [64]. The benefits of vitamin D supplementation appear to be most
Fig 3. Pair-wise scatter plot of number of neutrophils (neut), monocytes (mono), eosinophils (eosino) and lymphocytes (lymph) labelled by cluster
(red cluster 1, green cluster 2, blue cluster 3). Values on x and y axis denote cell concentrations x109/l.
doi:10.1371/journal.pone.0137377.g003
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evident in markedly inflammatory diseases where serum 25(OH)D concentrations are initially
low.
Although hypovitaminosis D in CE has traditionally been considered to be the result of
intestinal disease, there is growing evidence that hypovitaminosis D may contribute to the initi-
ation of intestinal inflammation. Intestinal epithelial vitamin D receptor is important in the
regulation of mucosal inflammation by maintaining the integrity of the mucosal barrier [65],
suggesting hypovitaminosis D may also perpetuate inflammation. However, the expression of
VDR is influenced by mucosal inflammation and is down-regulated by mucosal pro-inflamma-
tory cytokines [65, 66]. Studies in experimental models of inflammatory bowel disease have
demonstrated that vitamin D can have an anti-inflammatory effect. For example, in a murine
model of IBD, 1,25(OH)2D was shown to inhibit a number of genes involved in regulating
TNF-α production and signaling [67]. Furthermore, VDR knockout mice produce significantly
higher cytokine concentrations in response to chemically induced gastrointestinal inflamma-
tion than wild type mice [68]. These findings suggest that vitamin D is important in regulating
gastrointestinal inflammation. However, it is not clear whether these findings can be extrapo-
lated directly to patients with IBD. For example, CRP, ESR, TNF-α, IL-17, IL-10 and vascular
endothelial growth factor concentrations did not change following vitamin D3 supplementa-
tion in people with IBD [69]. Therefore, further work is needed to determine the role of vita-
min D in the treatment of inflammatory bowel disease in people and dogs.
There are some limitations to this study. The retrospective nature of this study made it
impossible to standardise the drugs and dietary treatments the dogs received prior to referral.
In addition, serum cytokine concentrations and gastrointestinal histology slides were not avail-
able from all dogs.
Conclusion
In summary, this study has shown that serum 25(OH)D concentrations are inversely associated
with markers of systemic inflammation in dogs with CE, and with severity of inflammatory
changes seen in histopathology samples. Further studies are required to assess whether low
vitamin D status is a cause or a consequence of inflammation.
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